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Figure 1-1. Sagittal view of the lower urogenital tract 
(Krongrad and Drollen, 1993). 
CHAPTER I 
 
INTRODUCTION 
Prostate overview 
The prostate is a male accessory reproductive gland commonly described as being about 
the size and shape of a walnut. The prostate is located below the bladder surrounding the 
urethra (Aumuller, 1989). The seminal vesicles, are diverticula of the Wolffian ducts and 
are attached to the prostate, between the rectum and the bladder (Josso, 1981). 
 
During ejaculation the prostate expels a proteolytic solution into the urethra. The fluid 
secreted by the prostate gland is rich in acid phosphatase, citric acid, the protease 
fibrinolysin, kallikreins 
(such as prostate 
specific antigen [PSA]), 
the enzyme amylase, 
fibronectin, 
phospholipids, 
cholesterol, zinc, 
calcium and many 
proteins with unknown 
function (Aumuller and 
Seitz, 1990). The proteins in the prostatic fluid modify the vaginal environment to support 
sperm survival in the female reproductive tract (Aumuller and Seitz, 1990). The anatomy 
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Figure 1-2. schematic diagram of the adult mouse 
genitourinary tract (lateral view). (Sugimura et al., 
1986b) 
of the human male reproductive tract is shown in Figure 1-1. The human prostate gland is 
located beneath the bladder and surrounds the first 3 cm of the urethra as it leaves the 
urinary bladder. The prostate is covered by a thin vascularized fibrous sheath surrounding 
a fibromuscular layer continuous with the smooth muscle surrounding the bladder. The 
fibromuscular layer extends within the organ and divide the gland into different zones 
(Kumar and Majumder, 1995; McNeal, 1980).  
 
Prostate structure 
The mouse prostate comprises 
four pairs of lobes named after 
their spacial orientation. These 
are: the anterior (AP), the 
ventral (VP), the dorsal (DP) 
and the lateral prostates (LP) 
(Figure 1-2). The DP and LP 
lobes are commonly referred to 
the dorsolateral prostate (DLP) 
due to their close position. The 
AP is also commonly referred to as the coagulating gland. The first discussion of the 
developmental organization of the human prostate was provided by Osward Lowsley in 
1912 (Lowsley, 1912). Lowsley‟s work was based on studies of fetal glands. He 
described five groups of periurethral embryonic tubules lobes: (a) middle (prespermatic 
 3 
and posturethral), (b) right lateral, (c) left lateral, (d) posterior (postspermatic and 
posturethral), and (e) ventral (anterior to the urethra). Several years after Lowsley‟s 
observation of the prostate, L. M. Franks challenged Lowsley‟s concept of prostatic lobes, 
finding no evidence of lobe boundaries (Franks, 1954a). Franks proposed that carcinoma 
could be found anywhere within the lobes. Frank‟s model has been criticized for a lack of 
anatomical precision. McNeal reported histological heterogeneity of the prostate gland 
with sub-division into prostatic zones (McNeal, 1980; McNeal, 1983). Currently, the 
overwhelming majority of pathologists and urologists follow McNeal's model and do not 
adhere to a lobar architecture in respect to human prostate (McNeal, 1984). 
 
McNeal Prostate 
In contrast to mouse 
prostate, which is 
comprised of four lobes, the 
concept of 5-lobed human 
prostate as proposed by 
Lowsley has been replaced 
by that of zonal architecture 
derived from McNeal.The 
human prostate is composed of 4 glandular zones which were described by McNeal. The 
prostate includes the peripheral zone, transition zone, periurethral zone and central zone. 
Each zone has their own ductal system (McNeal, 1980) (Figure 1-3). The peripheral zone is 
 
Figure 1-3. Zones of human prostate. 
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closest to the rectum and is the back part of the prostate gland,. It composes almost 75% of 
the normal prostate gland. Approximately 70% of prostate carcinomas arise in this zone 
(McNeal, 1969). The randomly oriented muscle fibers formed the stroma. The central zone 
composes 25% of the normal prostate and approximately 5-10% of prostate carcinomas 
arise from this zone (McNeal, 1969). Approximately 5-10% of the normal prostate gland is 
transition zone. In the transition zone, the stroma is more compact than peripheral zone, and 
the glandular architecture is similar to the peripheral zone. The transition zone is the place 
where benign prostatic hyperplasia (BPH) originates and approximately 20% of prostate 
carcinomas arise from this zone (McNeal, 1978).  
 
Prostate development 
During the seventh week of human fetal development, the male and female urogenital 
systems are anatomically indistinguishable. Both the male and female embryos have a pair 
of undifferentiated gonads and two sets of ducts: the paramesonephric (Mullerian) ducts 
and the mesonephric (Wolffian) ducts. In males, gonads differentiate into the testes, which 
produce testosterone and Mullerian inhibiting substance (Jost, 1947). The Wolffian ducts 
are stabilized by testosterone and its metabolites, while in males Mullerian ducts regress 
because of the presence of Mullerian inhibiting substance except the extreme ends (Jost, 
1947). The lower end of the Mullerian tubercle is involved in the subsequent formation of 
the prostate utricle. Testosterone is required for late-stage Wolffian duct differentiation. 
These ducts differentiate into epididymis, ductus deferens, ejaculatory duct and seminal 
vesicles. (Anderson and Liao, 1968; Imperato-McGinley et al., 1985; Imperato-McGinley 
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et al., 1974; Walsh et al., 1983; Walsh et al., 1974). The urogenital sinus is also a 
component of the ambisexual stage in both male and females. In males, it develops into 
bladder, urethra, prostate, bulbourethral (in humans, Cowper‟s) glands, and periurethral 
glands under the influence of DHT (5-dihydrotestosterone), which is a potent mitogenic 
hormone (Anderson and Liao, 1968; Bruchovsky and Wilson, 1968; Imperato-McGinley et 
al., 1974). The female urogenital sinus can form prostate in response to androgens. It was 
determined by growing embryonic female urogenital sinuses from 13 to 18 day old 
embryonic mice and vaginas from 1 to 30 day old mice as grafts to male mouse hosts. All 
embryonic urogenital sinuses as well as vaginas from 1 day old mice were responsive to 
androgens and formed prostate, however, vaginas from mice 5 or more days old never 
formed prostate (Cunha, 1975). It was found that the developmental response of the 
age-dependent loss in responsiveness of the intact vagina to androgens results from an age- 
dependent loss in the ability of vaginal stroma to participate in prostatic morphogenesis. 
These data emphasize the importance of stromal factors during prostatic morphogenesis 
(Cunha, 1975). 
 
Stromal-epithelial interaction in prostate development 
The stroma encompasses all of the non-epithelial components of an organ. For most organs, 
stroma is mainly composed of fibroblasts, smooth muscle cells, blood vessels, nerves and 
fat cell etc. The predominant cells in adult prostates are smooth muscle cells.  
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The prostate develops from the embryonic urogenital sinus as a result of interactions of 
urogenital sinus epithelium (UGE) and urogenital sinus mesenchyme (UGM). Prostate 
development is controlled by steroid hormones that induce and maintain a complex cross 
talk between the stromal and epithelial cells (Cunha et al., 1992). The result of this 
intercellular communication depends upon the context and differentiation status of the 
cell type being stimulated (Hayward and Cunha, 2000; Hayward et al., 1998). In 
developing fetal prostate, DHT binds to the androgen receptors on mesenchymal cells to 
send signals to adjacent epithelium, inducing epithelial ductal brunching morphogenesis; 
expression of epithelial androgen receptors; regulation of epithelial cell proliferation; and 
specification of the expression of prostatic lobe-specific secretory proteins (Chung and 
Cunha, 1983; Cunha et al., 1987; Hayashi et al., 1993; Sugimura et al., 1986a; Takeda et 
al., 1990). Concurrently, the developing prostatic epithelium induces the differentiation 
and morphological patterning of smooth muscle in the UGM (Hayward et al., 1998; 
Hayward et al., 1997). In the healthy adult prostate, both epithelial and stromal 
compartments are highly differentiated. While under steady state concentration of 
androgen, the highly differentiated stroma is in close contact with highly differentiated 
and functional epithelium to maintain prostate homeostasis. The normal prostatic 
epithelial growth is regulated by reciprocal smooth muscle-epithelial cell interactions 
which are mediated by the local synthesis and action of paracrine signaling molecules 
(Hayward et al., 1997).  
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Abnormalities in smooth muscle-to-epithelial signaling may either actively promote 
carcinogenesis or permit the progression to neoplasia through the loss of restriction of 
normal homeostatic controls (Grossfeld et al., 1998; Hayward et al., 1998). Thus, the 
process of prostatic carcinogenesis may include aberrations in the interactions of the 
prostatic epithelium, with its smooth muscle microenvironment resulting in reciprocal 
de-differentiation of both the emerging carcinoma cells and the prostatic smooth muscle.   
 
Prostate disease. There are a number of diseases of the prostate, which can be divided 
into cancerous prostate problems, and non-cancerous prostate problems. The clinical 
conditions of non-cancerous prostate disease include the following: 
 
(1) Prostatism. A disease caused by urethra compression or obstruction, due most 
commonly to benign prostatic hyperplasia of the prostate gland. Symptoms include 
urination difficulties and, occasionally, urine retention. Prostatism can interfere with 
bladder urine flow rate (Hamilton et al., 2006).  
 
(2) Prostatitis. A disease resulting from inflammation of the prostate gland. 25 percent of 
men who have genital and urinary problems may have prostatitis (De Marzo et al., 2007). 
Prostatitis is composed of four disorders:  
(a) Acute bacterial prostatitis: the least common type of prostatitis and easy to 
diagnose and treat. Symptoms include fever, pain, increased white blood cells and 
 8 
bacteria in the urine. Since the symptoms are caused by bacteria, an appropriate antibiotic 
is the treatment of choice for this type of prostatitis (Hua and Schaeffer, 2004). 
(b) Chronic bacterial prostatitis: uncommon and often associated with defects in the 
prostate. Therefore, effective treatment includes removing the defect and treating with 
appropriate antibiotics (Hua and Schaeffer, 2004).  
(c) Chronic prostatitis/chronic pelvic pain syndrome is the most common but least 
understood type of prostatitis (Rivero et al., 2007). It can be either inflammatory or 
noninflammatory. Men of any age can have this problem and the symptoms can appear 
sporadically. Antibiotics may not be the suitable choice because there is no solid evidence 
of bacteria infection in either types.  
(d) The fourth type of prostatitis is asymptomatic inflammatory prostatitis. There are 
infected cells in the semen but may not cause any symptoms (Simardi et al., 2004). It can 
be associated with infertility or prostate cancer . 
 
(3) Benign prostatic hyperplasia (Also called BPH or benign prostatic hypertrophy). An 
enlarged prostate is a sign of this disease. BPH is the most common prostate problem. 
Although it is not cancer, BPH symptoms are often similar to those of prostate cancer. It 
can cause discomfort and urinary problems. BPH represents an overgrowth of epithelial 
nodules and stroma tissue in the transition zone of the prostate. At cellular level, basal 
cell hyperplasia and increased stromal mass are commonly seen in BPH (Bostwick et al., 
1992). Advanced age and circulating androgens are the two well-established risk factors 
for BPH (Isaacs and Coffey, 1989). Autopsy data indicated that the presence of 
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microscopic BPH (histologically) in 80% of males at 71-80 and 90% at 81-90, however the 
incidence of microscopic BPH is greater the clinically detectable disease (Berry et al., 
1984). Enlargements of prostate cause increasing pressure within the bladder causing 
frequently contractions even only a small amount of urine is present. Eventually, the 
bladder loses the ability to empty itself, causing many problems.  
 
The prostate is regulated by sex-steroid hormone levels. Androgens and estrogens are 
important for prostate cell growth. Estrogen is generated through stromal aromatization of 
androgen and the ratio of estrogen/androgen increases in BPH patients (Roberts et al., 
2004; Shibata et al., 2000). As men age, lower concentration of testosterone and higher 
concentration of estrogen are found in the blood.. Studies have suggested that BPH may 
occur because the higher amount of estrogen increases smooth muscle cell proliferation and 
differentiation (Zhang et al., 1997). Anti-estrogens such as aromatase inhibitors 
(testolactone) which prevents conversion of androgen to estrogen have been used in the 
treatment of BPH patients (Royuela et al., 2001).  
 
The conversion of the main androgenic steroid testosterone to dihydrotestosterone (DHT) 
is catalyzed by the 5-reductase isoenzymes Types 1 and 2. DHT is required for secretory 
epithelial cells function. 5-reductase Type 1 is most prevalent in the liver and the skin, 
with minimal amounts found in the prostate, whereas Type 2 is most prevalent in the 
prostate . In the prostate, DHT is generated by 5-reductase type 2. Higher 5-reductase 
activity has been demonstrated in BPH as compared to in normal tissue (Silver et al., 1994). 
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Clinically, finasteride (a 5-reductase type 2 inhibitor) has been used to treat BPH patients 
(Bautista et al., 2003; Sandhu and Te, 2004). 
 
Many growth factors (including: fibroblast growth factor [FGF] family members, insulin 
like factors [IGF], transforming growth factor  [TGF-, transforming growth factor s 
[TGF-, andepidermal growth factor [EGF]), mediate epithelial-stromal interaction to 
sustain prostate homeostasis. Increased FGF2 levels have been found in early stages of 
BPH patients (Mori et al., 1990). Transforming growth factor 1 (TGF-1) expression and 
secretion have also been shown to increase in BPH patients (Mori et al., 1990). Low 
concentrations of TGF-increase cell proliferation, but high concentrations inhibit 
stromal cell growth (Kassen et al., 1996). TGF-treatment could generate a reactive 
stroma composed of myofibroblasts and fibroblasts which express extra cellular matrix 
components and stromal cell markers, such as -smooth muscle actin, calponin and 
tenascin (Peehl et al., 1997; Tuxhorn et al., 2002). Elevation of a variety of factors 
influences extracellular matrix production and secretion, which is similar to the stroma of 
BPH patients (Untergasser et al., 2005). 
 
(4) PIN (Prostatic Intraepithelial Neoplasia). PIN has been identified as the most likely 
precursor lesion for prostatic carcinoma. The term was introduced in 1987 by Bostwick and 
Brawer (Bostwick and Brawer, 1987; Mikuz, 1997). PIN indicates the progressive 
abnormalities of phenotype and genotype that are similar to cancer rather than normal 
prostatic epithelium. PIN is strongly predictive of adenocarcinoma (Webber et al., 1995). 
 11 
 
 
Figure 1-4. Role of inflammation in prostate carcinogenesis. 
(Nelson et al., 2004). Copyright @Massuchusetts Medical 
Society. 2003 
Two grades of PIN:low-grade PIN (LGPIN), and high-grade PIN (HGPIN)), has been used 
for diagnosis. However, many pathologists no longer report the presence of LGPIN and 
note only the histologic findings associated with HGPIN.  
 
(5) Prostate cancer. Early stage prostate cancer is not lethal, but can progress to become a 
systemic malignancy. Cancer grows in the interior of the prostate gland, but can spread to 
surrounding tissues near the prostate, such as the seminal vesicles and bladder and can 
metastasize to distant organs of the body prominently including bones, liver and lymph 
nodes (Coffey and Pienta, 1987). Early stage of prostate cancer can be treated successfully, 
but metastasized tumors are often lethal. Prostate cancer is the most common type of 
non-skin cancer in men in the United States and is the second leading cause of cancer death 
in men. It was estimated that 27,050 men in the United States will die of prostate cancer in 
2007 (American Cancer Society, 2007). African American men have the highest incidence 
of prostate cancer, 
and Asian and 
Native American 
men have the 
lowest incidence. 
Rates for Asian 
and African men 
increase 
dramatically when 
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they emigrate to the United States, suggesting an environmental (probably diet related) 
connection.  
 
It has been suggested that inflammation may contribute to the risk of developing prostate 
cancer (Goldstraw et al., 2007). Although there is no conclusive data supporting a role for 
inflammation in the pathogenesis of prostate cancer, there are accumulating data in favor 
of this idea. Inflammatory cytokines and genotoxic reactive oxygen radicals produced by 
microbial infections can increase cell proliferation and promote tumorigenesis (Dennis et 
al., 2002). Some pathologists have proposed inflammation as a factor in the etiology of 
prostate cancer (De Marzo et al., 2007). Chronic inflammation is commonly found in the 
peripheral zone of the prostate adjacent to foci of PIN or prostate cancer. The lesions are 
thought to form as a consequence of the regenerative proliferation of epithelium in 
response to injury caused by inflammatory oxidants (Hsieh-Li et al., 1995). The 
suggested pathway is shown in Figure 1-4.  
 
Gleason Score 
The Gleason score was established in 1966 by pathologist Dr. Donald Gleason, and has 
been widely used to diagnose prostate cancer (Gleason, 1977). He gathered biopsy 
information from nearly 3000 prostate cancer patients and developed a histopathologic 
scoring system. The score is based on the glandular histological patterning and cytological 
appearance. The Gleason score is used to help evaluate the prognosis of men with prostate 
cancer. Together with other parameters, it is used to predict prognosis and identify the best 
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Figure 1-5 Gleason score system 
(Gleason D, 1974) 
treatment strategy for prostate cancer.  
 
In a biopsy specimen the pathologist takes the two most prominent patterns or scores 
(scores ranges from 1 to 5) . The scores are added to obtain the final Gleason score. The 
Gleason score ranges from two to ten. A Gleason score of two is associated with the best 
prognosis and a score of ten with the worst. For example, a prostate biopsy specimen may 
be diagnosed by two scores, one is two and the other number is three. The final Gleason 
score in this case would be five. Gleason scores are associated with the following features 
(Figure 1-5): 
Grade 1. The cancerous prostate closely resembles normal prostate tissue. The glands are 
small, well-formed, and closely packed. 
Grade 2. The tissue still has well-formed glands, but they are larger and have more stroma 
tissue between them. 
Grade 3. The tissue still has recognizable 
glands, but the cells are darker. Some of the 
cells are beginning to infiltrate the 
surrounding tissue. 
Grade 4. The tissue has few recognizable 
glands. Many cells are invading the 
surrounding tissue. 
Grade 5. The tissue does not have 
recognizable glands. There are often just sheets of cells throughout the surrounding tissue.   
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Risk factors for prostate cancer. The major risk factors for prostate cancer include 
genetic, dietary, and environmental factors that affect male hormones (such as DHT 
production) and make men more susceptible to this cancer.  
 
(1) Age. Age is the most important epidemiological risk factor for prostate cancer 
(Greenlee et al., 2001). As the population ages, new cases of prostate cancer will increase 
significantly. It is estimated that by age 70, about 65% of men have at least microscopic 
evidence of prostate cancers. There is a positive correlation between time and prostate 
cancer progression.  
 
(2) Family History. It has been suggested that heredity may play a role in prostate cancer. 
Men with a family history of prostate cancer may have a higher risk of having this disease 
(Damber, 1998; Gann, 2002; Lesko et al., 1996).  
 
 (3) Ethnicity. African American men have the highest risk for prostate cancer, more than 
50% higher than the risk for Caucasian American males (Bloom et al., 2006; Gann, 2002; 
Powell, 2007). Asian men have a lower risk for prostate cancer, but their risk increases if 
they move to North America (Lee et al., 2007). Therefore, environmental or dietary factors 
might be associated with the risk of developing prostate cancer.  
 
(4) Dietary Factors. A high-fat diet may increase the risk of prostate cancer. Researchers 
theorize that fat increases production of the hormone testosterone, which may promote the 
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growth of prostate cancer cells. Specific fat subtypes may influence cancer cell growth. A 
higher ratio of omega-3 fat acid/omega-6 fat acid can suppress prostate cancer cell growth 
(Kobayashi et al., 2006). Because prostate cancer is rare in many parts of Africa, it has been 
postulated that dietary factors may play a role in African American men and may put them 
at higher risk. HAs (heterocyclic amines), a group of carcinogens known as PhIP 
(2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), is found in grilled beef, pork, 
chicken, lamb, and fish. It has been indicated that PhIP relates to prostate cancer incidence 
(Tang et al., 2007).  
 
(5) Exposure to Chemicals. The relationship between prostate cancer and chemical 
exposure is controversial. Men whose work involves heavy labor and those exposed to 
certain metals and chemicals, including cadmium, dimethyl formamide, and acrylonitrile, 
may be at higher risk for prostate cancer (O'Berg et al., 1985; Walrath et al., 1989). Some 
studies have indicated that farmers might be also be at higher risk (Parker et al., 1999).  
 
(6) Infection and Inflammation. Genetic factors that affect the body's response to viruses 
can also associate with inherited prostate cancer. Some association has been seen between 
prostate cancer and bacterial or viral infections, such as herpesvirus, human 
papillomavirus, and cytomegalovirus. It was suggested that men with genetic 
susceptibilities could develop a chronic inflammatory condition in the prostate by viral 
infection and possibly initiate cancerous changes. It proposed that exposure to 
environmental factors such as infectious agents and dietary carcinogens, and hormonal 
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imbalances could lead to prostate injury and  develop chronic inflammation and 
regenerative „risk factor‟ lesions, referred to as proliferative inflammatory atrophy (PIA), 
which could progress to PIN (prostatic intraepithelial neoplasia) and eventually invasive 
carcinoma (De Marzo et al., 2007). However, some recent studies have shown that there is 
no link between viral infections and prostate cancer development (Bergh et al., 2007).  
 
 (7) Smoking. Cigarette smoking may increase the risk of prostate cancer by affecting 
circulating hormone levels or through exposure to carcinogens (Plaskon et al., 2003). A 
few hypothetical mechanisms were proposed to enhance the risk of prostate cancer. It has 
been suggested that smoking can increase the circulating levels of bioavailable 
testosterone and lower levels of bioavailable estradiol in men (Ferrini and Barrett-Connor, 
1998). There are significant positive correlations between cigarettes smoked/day and 
serum total androstenedione as well as total and free testosterone in men (Dai et al., 
1988). Data from a population based case-control study suggest that smoking is a risk 
factor of prostate cancer Current smokers appear to be at moderately increased risk for 
this disease compared with non-smokers (Plaskon et al., 2003).  
 
Procedures used to evaluate prostate problems  
Blood and urine laboratory tests are necessary for men during their annual physical 
examinations. Evaluation of the prostate gland is also recommended by the National 
Cancer Institute and the American Cancer Society. 
 (1) DRE (digital rectal examination). A digital rectal examination is performed to 
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examine abnormalities of the prostate (Sneyd et al., 2003; Villers et al., 2003). Enlargement 
of the prostate gland can be found in BPH patients. An irregular or hard lump may indicate 
the presence of a tumor. However, the digital rectal exam is not the best method of 
detecting prostate cancer because not all abnormalities in the prostate can be found through 
the rectum without performing histological examination of the prostate tissue.  
 
(2) Blood prostate-specific antigen (PSA) test. PSA was discovered in 1970 by Ablin, and 
PSA testing has been widely used and is the most important method to detect prostate 
cancer (Ablin, 1997). PSA is a kallikrein serine protease that is secreted by prostate 
epithelial cells diffuses into the bloodstream in areas of tissue damage caused by, for 
example, inflammation or cancer. Morphological and histological changes of the prostate 
lead to leakage of PSA into blood. PSA levels higher than 4.0 ng/ml may indicate prostate 
disease (infection, enlargement of the prostate gland or prostate cancer). PSA testing is 
commonly recommended for men over 50. A PSA blood test can be done alone or in 
conjunction with DRE to improve the odds of detecting prostate cancer (Webber et al., 
1995). PSA is the only serum marker recommended by American Cancer Society to screen 
for prostate cancer, and the value is limited because of its lack of specificity and sensitivity. 
The cutoff upper limit of 4.0 ng/ml is still under debate. There is strong evidence that a PSA 
cutpoint of 4.0 ng/ml actually misses the majority of prostate cancers, up to 15% of which 
may be potentially aggressive cancers (Thompson et al., 2005).  
 
(3) Prostate-specific membrane antigen (PSMA) test. PSMA is an integral glycoprotein, 
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and was shown to be overexpressed in prostate tumor epithelial cells and serum of cancer 
patients. Studies have suggested that PSMA correlates with Gleason score and stage of 
prostate cancer. Despite its expression by subsets of various types of malignancies, such as 
urothelial carcinomas of the bladder, PSMA is still considered to be relatively sensitive and 
highly specific for prostate cancer (Mhawech-Fauceglia et al., 2007).  
 
Other molecular markers such as prostate stem cell antigen, early prostate cancer antigen, 
hepsin, enhancer of zeste homolog gene 2, human glandular kallikrein 2, transforming 
growth factor-1, chromogranin A have been suggested as potential promising biomarkers 
for prostate cancer.  
 
If the DRE or PSA levels are unusual, ultrasound can also be performed to examine 
prostate cancer candidates. (Franco et al., 2000) 
 
(4) Transrectal ultrasound (TRUS). Prostate enlargement, cancer nodules, and tumor 
invasion to the seminal vesicles can all be found by ultrasound. TRUS can also be used 
for guidance of needle biopsies of the prostate gland (Mikuz, 1997). 
  
(5) Computed axial tomography scan (CAT scan). The combination of x-rays and 
computer technology can produce horizontally and vertically cross-sectional images , of 
the prostate. Abnormalities within the prostate gland can be found by CT scan, but 
additional tests such as PSA test should be used in combination to diagnose prostate cancer 
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(Golimbu et al., 1981). 
 
(6) Magnetic resonance imaging (MRI). This technique uses a combination of large 
magnets, radiofrequencies, and a computer to produce detailed images of organs and 
structures within the body (Vilanova and Barcelo, 2007). Prostate abnormalities can 
found by MRI. 
 
(7) Biopsy. A procedure in which tissue samples are removed from the prostate, and are 
examined under a microscope. A pathologist can examine the slide to determine if cancer 
is present within the prostate. Cancer cells have large nuclei, increase nuclei/cytoplasm 
ratio compared with normal cells. False-negative results might occur and some patients 
will need rebiopsy (Hori et al., 2006). Combination of endorectal MRI and magnetic 
resonance spectroscopy imaging (MRSI) might be a useful tool to decrease rebiopsy rate 
(Amsellem-Ouazana et al., 2005). 
 
Treatment of prostate cancer 
(1) Surgery. Radical prostatectomy is the most common therapy for early stage prostate 
cancer. The ideal responsive candidate can live 10 to 20 years after surgery. Radical 
prostatectomy is a major surgery performed to remove the entire prostate gland and the 
surrounding tissues such as the seminal vesicles. Lymph nodes can also be sampled for 
biopsy to examine if the cancer has metastasized or not. The goal is to remove the cancer 
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entirely and prevent its spread to other parts of the body. The risks after surgery include 
impotence, heart attack, stroke, blood clots, infection or bleeding like other surgeries.  
 
(2) Radiation therapy. Radiation therapy has been used in the treatment of prostate cancer for 
several decades (Zagars and Pollack, 1995). Prostate cancer is a radiation-sensitive neoplasm 
that demonstrates a classic sigmoid dose response curve to X-rays. Higher volume tumors 
need higher radiation doses. Tissues such as bladder and rectum are at risk when radiation is 
performed. 
 
(3) Hormone therapy. Hormone therapy blocks action of hormone and stops cancer cells 
from growing. Luteinizing hormone-releasing hormone agonists are potent inhibitor of 
gonadotropin secretion. Following an initial stimulation of gonadotropins, chronic 
administration of leuprolide acetate results in suppression of testicular steroidogenesis. 
Administration of luteinizing hormone-releasing hormone agonists has resulted in 
inhibition of the growth of certain hormone dependent tumors (such as prostatic tumors). 
Examples are leuprolide, goserelin, and buserelin. Antiandrogens exerts its action by 
inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen to the 
androgen receptors on prostatic cells. Such as flutamide and  nilutamide. 
  
Studies are still being carried on to find the ideal therapy for localized prostate cancer. 
Currently, the two most common therapies used in the United States to treat prostate 
cancer remain radical prostatectomy and radiation therapy (Frank et al., 2007; Rossi, 
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2006). The newer focal therapy consists of cryoablation techniques and heat 
energy–based treatments [high intensity focused ultrasound (HIFU), radiofrequency 
interstitial tumor ablation (RITA), and thermal brachytherapy] (Zhao et al., 2006). 
Radioactive seeds were first used by Dr. Anthoy D'Amico at Harvard Medical School to 
treat early stages of prostate cancer. Magnetic resonance imaging (MRI) was used to 
place 100 radioactive seeds into tumors inside prostate to destroy cancer cells. For some 
patients, it may be superior to the usual methods of surgical removal of the gland.  
 
Animal models of prostate cancer 
(1) Transgenic models. There are a limited number of promoters which were used to 
introduce transgenes to prostate epithelial cells. The probasin promoter is one of them. It 
includes the minimal promoter, long promoter and composite promoter containing multiple 
androgen response elements. 
 
TRAMP and LADY mouse models are two well-known animal models used to investigate 
prostate cancer progression (Masumori et al., 2001; Matusik et al., 2001). The TRAMP 
model uses the minimal rat probasin promoter to forcibly express the SV40 early genes (T/t 
antigen:Tag) specifically targeted to the terminally differentiated tall columnar epithelial 
cells of the mouse prostate. Male TRAMP mice develop progressive prostate disease that 
histologically and pathologically mimics human disease with metastatic spread to distant 
sites. The LADY mouse model uses a long probasin promoter to express large T antigen. It 
elicited a higher level of expression in the mouse prostate that was developmentally and 
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differentially regulated by androgen. The LADY model is advantageous in that expression 
is high but the disease progression is less aggressive with no metastasis (Abate-Shen and 
Shen, 2002). Although both the TRAMP and LADY models offer many advantages, they 
both differ from the human disease in their rapid onset and frequent occurrence of 
neuroendocrine tumor (Abate-Shen and Shen, 2002). The C3(1)-Tag mice also develop 
progressive prostate cancer, but tumors can be found in other tissues as well, which limits 
its use to prostate cancer research. Cryptdin-2-T and Gg-SV40 T also develop progressive 
prostate cancer, however the promoters used to drive SV40 large T antigen are not prostate 
specific.  
 
Other genes such as c-myc (Zhang et al., 2000), Ras and Fgf8b (Song et al., 2002) have 
been suggested to play a role in prostate cancer progression. These genes have been used in 
mouse models. However, in the majority of these models, only a relatively mild phenotype, 
such as hyperplasia or PIN, instead of adenocarcinoma was seen (Abate-Shen and Shen, 
2002).  
 
(2) Knockout models. Deletion of a gene of interest is another way to generate mouse 
models (Sharma and Schreiber-Agus, 1999). PTEN heterozygous knockout mice, Nkx3.1 
null and p27 null mice have displayed prostate phenotypes (Lei et al., 2006). The loss of 
these genes has been suggested to play a role in the development of human prostate cancer, 
and this theory is supported by observations in the knockout mice. Similar to transgenic 
mouse models, the resulting phenotypes in these knock out mice were hyperplasias as well. 
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Because of embryonic lethality of specific ablation, conditional knock out mice were 
generated by applying the PSA promoter to drive prostate-specific Cre expression. The 
targeted gene was inactivated by PSA-Cre targeted deletion of the floxed region resulting 
in the expression of a truncated protein lacking the gene function. It was found that 
targeted biallelic inactivation of Pten in the mouse Prostate leads to prostate cancer (Ma et 
al., 2005b). 
(3) Canine models. Dogs are the only species besides humans that develop spontaneous 
prostate cancer with high frequency (Waters and Bostwick, 1997; Waters et al., 1997). 
Dogs also display a high frequency of metastasis, especially to the bone (Rosol et al., 
2003). Compared to other animal models, the use of dog models is limited, because the 
high expense to maintain dog colonies and the progression of cancer is slow and thus time 
consuming (Waters et al., 1998).  
 
(4) Rat models. Several Lobund-Wistar, Dunning, and Noble rat models have been used 
extensively to study prostate cancer progression. Rats are one of the few species that 
spontaneously develop prostate adenocarcinomas. The Dunning rat model is the most 
common model and is widely used for nutritional studies (Dunning, 1963). Lobund Wistar 
was shown to have an increased incidence of prostate cancers in the anterior prostate 
(Pollard, 1992; Pollard, 1998). Noble rat have been used to study hormone-induced 
prostatic carcinogenesis and it was shown that IGF-1 and VEGF may be the critical 
regulators in mediating epithelial-stromal interactions in sex hormone-induced prostate 
carcinogenesis (Wang and Wong, 1998). However, these models are limited by long tumor 
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latencies, and lack of spontaneous metastases (Bostwick, 2000). 
  
Human models  
(1) Xenografts and orthotopic models. Cell lines, such as CWR22, LAPC and LNCaP cells, 
which were isolated from primary tumors or metastasized tissues can be injected 
subcutaneously or orthotopically in the severe combined immune deficiency (SCID) 
mice or nude mice (van Weerden and Romijn, 2000). They represent a range of malignant 
potential and also display differential responses to androgens. However, the cells are 
already transformed therefore limit their use to the study of prostate cancer initiation.  
 
(2) Tissue recombination and xenograft. The tissue recombination technique was studied in 
detail in the Cunha lab. To date this technique is one of the best models to study 
stromal-epithelial interactions. Epithelial cells are combined with stromal cells in a 
collagen gel, and grafted under kidney capsule of SCID or nude mice. Genes of interest can 
either be overexpressed or knocked down in a tissue specific manner. Based on the size and 
histology of the graft, the function of the gene can be examined. There are limited human 
models of prostate cancer progression. This technique can provide new insights to prostate 
cancer research (Hayward et al., 1998; Hayward, 2002) 
 
Virtues of BPH-1 cells and its derivatives  
Prostate cancer research has been hindered by a lack of well established, characterized, 
immortalized  benign prostatic epithelial cells lines that express markers of normal 
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prostatic epithelial cells. Such cells can used to study multistep carcinogenesis, cancer 
progression and study potential therapeutic agents to inhibit prostate cancer growth. 
BPH-1 cell line is one of such cell line has been widely used in prostate cancer research. 
It is by far the only line which start off benign an can by pushed into malignant 
phenotypes by either genetic modification or hormone treatment.  
 
(1) BPH-1 cell lines. BPH-1 cell line was established and characterized in 1995 by Dr. 
Simon W. Hayward (Hayward et al., 1995). Prostate tissues were isolated from a 68 
yr-old BPH patient undergoing transurethral resection of the prostate for urinary 
obstruction. The stromal fraction was separated from prostatic epithelial organoids by 
repeated unit gravity sedimentation. Epithelial cells from the organoid were immortalized 
by infection with the Zippneo SV virus carrying the large SV40 T antigen, which was 
used in establishment of LAZY mice. Resistant colonies were selected using 800 g/ml 
Geneticin in the culture medium and then expanded. Morphology of BPH-1 cells showed 
an even cobblestone appearance typical of epithelial cells which was similar to primary 
cultured prostatic epithelial cells. The expression profile of cytokeratin was consistent 
with luminal epithelial cells. BPH-1 cells respond to a number of different growth factors, 
such as EGF family and TGF-, EGF and TGF- stimulate BPH-1 cells proliferation, but 
TGF-1 and TGF-2 inhibit cell proliferation. Based on the fact that androgen receptor 
(AR) is induced by the urogenital sinus mesenchyme during development (Cunha et al., 
1980; Neubauer et al., 1983), the loss of AR expression in this cell line may be due to 
lack of inductive stromal signal. Grafting or injecting BPH-1 cells to male nude mice 
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could not demonstrate any tumorigenic response up to1 year (Ricke et al., 2006). 
However small clumps of cells could still be found in the grafts which demonstrated that 
cells were still viable in the host animals. This phenomenon indicated that BPH-1 is a 
benign prostatic epithelial cell which can be used as a parental cell line to generate 
derivative cell lines in order to study genes function. Modification of expression levels of 
oncogenes and tumor suppressors in BPH-1 cells can be utilized to study functions of 
those genes in prostate cancer progression. 
 
(2) BPH-1
CAFTD
 lines. Majority of human prostatic cancers arise as adenocarcinomas 
which are derived from the epithelial cells that form the glands and ducts of the prostate. 
As the carcinoma evolves, alterations in gene expression also occur in the adjacent 
stroma. These “changes” may enhance the invasive potential of the epithelial tumor (Ao 
et al., 2007; Grossfeld et al., 1998). BPH-1 cells can be induced to undergo malignant 
changes either by association with tumorigenic stromal microenvironment or by treatment 
with hormonal carcinogens (Olumi et al., 1999; Wang et al., 2001). It has been shown that 
carcinoma associated fibroblast (CAF) direct tumor progression in initiated human 
prostatic epithelium, while normal prostatic fibroblasts were incapable of stimulating 
such progression (Olumi et al., 1999).  
 
BPH-1 cells are considered to be initiated since they are SV-40 immortalized, therefore 
they are susceptible to further genetic changes to progress to a malignancy. The epithelial 
cells derived from these tumors (BPH1
CAFTD
) are tumorigenic without the stimulation of 
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stromal cells when re-grafted to mice. The data demonstrated for the first time that 
genetically initiated, non-tumorigenic epithelial cells can undergo a permanent malignant 
change with previous exposure to CAFs. Tissue from BPH-1 + CAF recombinants were 
put into culture and resistant epithelial cells were selected by G418. Four sublines were 
isolated from these tumors which were subsequently designated as BPH-1
 CAFTD
-1, -3, -5 
and –7. These lines were then regrafted to SCID mice and further cell selection was 
performed from which BPH-1
 CAFTD
-2, -4, -6 and –8 were derived (Hayward et al., 2001). 
All eight derivatives are tumorigenic in SCID mice. Tumors recapitulate small acinar 
prostatic carcinoma or squamous carcinoma. Although different CAF populations were 
used to recombine with BPH-1 cells to generate the 4 BPH-1
CAFTD
 derivatives, all 
BPH-1
CAFTD
 lines share recurrent chromosomal rearrangements. This finding indicated 
that common genetic changes can be induced by stromal environment through paracrine 
interactions.  
 
(3) BPH-1
TETD
. Previous data demonstrated that the non-tumorigenic BPH-1 cells can be 
induced to be form tumors under the influence of testosterone and estrogen (T+E2) as a 
result of paracrine signaling transduction (Wang et al., 2001). The cell lineages 
(BPH-1
TETD
-A and BPH-1
TETD –B) derived from the hormonally induced tumors are also 
tumorigenic like BPH-1
CAFTD
 lines. It demonstrated that stromal cells are required for this 
hormonally induced carcinogenesis (Hayward et al., 2001). The malignant potential of the 
isolated epithelial cells from the hormone induced tumors demonstrated BPH-1 cells are 
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permanently transformed under the influence of T + E2. BPH-1
TETD  
lines shared similar 
chromosome amplifications seen in BPH-1
CAFTD
 strains.  
 
BPH-1 and its derivatives have been widely used to study prostate carcinogenesis and 
evaluate stromal-epithelial interactions during carcinogenesis. These models allow for 
genetic manipulation of epithelium and stroma. The commonalities of these models, other 
conventional human models (RWPE, RC165N) and human prostate cancer progression 
(PRCA) are outlined Tables 1, 2, 3 which tabulate the abundant preliminary data using 
immunohistochemical, PCR, rtPCR, Western analysis, immunoprecipitation, gene 
expression array, SNP array and proteomic techniques (Data provided by Dr. William 
Ricke). The vast number of similarities between these models and human PRCA validates 
and justifies the use of these models in the study of PRCA-progression. Moreover, this 
model is well suited to address stromal-epithelial interactions during PRCA-progression. 
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Table 1. A comparison of human cell lines to human primary prostate epithelial cells 
grown in vitro. 
 Criteria                                    
Cells 
RWPE-1 RC165N BPH-1 
BPH-1
C
AFTD
 
Primary 
human    
References 
Keratins-8,18 + + + 
+ 
+ 
PD (Bello et al., 1997; Gu et 
al., 2005; Gu et al., 2006; 
Hayward et al., 1995)  
Keratin-14 - NT - 
 
- + 
(Bello et al., 1997; Gu et 
al., 2005; Gu et al., 2006; 
Hayward et al., 1995)  
chromogranin-A NT NT -  - UF 
AR mRNA + + + 
 
- + 
PD (Hayward et al., 1995; 
Lau et al., 2000) 
AR protein + + - 
- 
- 
PD (Bello et al., 1997; Gu 
et al., 2005; Gu et al., 
2006)  
PSA mRNA + - - 
 
- 
- 
UF (Bello et al., 1997; Gu 
et al., 2005; Gu et al., 
2006; Hayward et al., 
1995) 
pS2 NT NT - NT - (Lau et al., 2000) 
AR and glandular 
epithelium induction 
by stroma 
 
NT 
 
NT 
+ 
 
NT 
+ 
PD, UF (Cunha et al., 
1983; Lang et al., 2001a; 
Lang et al., 2001b; Wang 
et al., 2001) 
PSA induction by 
stroma 
NT NT NT 
 
NT + 
(Cunha et al., 1983; Lang 
et al., 2001a; Lang et al., 
2001b) 
E-cadherin NT NT + 
 
+ + 
UF (Bello et al., 1997; Gu 
et al., 2006; Hayward et 
al., 1995)  
in vitro: proliferation, 
forms mono-layers, 
cobblestone 
morphology 
 
+ 
 
+ 
 
+ 
 
 
 
+ 
 
+ 
 
 (Bello et al., 1997; Gu et 
al., 2006; Hayward et al., 
1995)  
Nontumorigenic in 
vivo 
+ + + 
 
- + 
 (Bello et al., 1997; Gu et 
al., 2005; Gu et al., 2006; 
Hayward et al., 1995 ) 
Immortalization HPV hTert 
SV-40 
Tag 
SV-40 
Tag - 
(Bello et al., 1997; Gu et 
al., 2005; Gu et al., 2006; 
Hayward et al., 1995) 
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Zinc content NT NT  +
*
 NT + (Feng et al., 2002) 
TGFinhibited + NT + 
- 
+ 
(Ao et al., 2006; Bello et 
al., 1997; Gu et al., 2005; 
Gu et al., 2006; Hayward 
et al., 1995) 
EGF, FGF-2, -7  
stimulated growth 
+ NT + 
 
NT + 
(Bello et al., 1997; Gu et 
al., 2005; Gu et al., 2006; 
Hayward et al., 1995)  
Race cs aa cs 
 
 
cs 
n/a 
(Bello et al., 1997; Gu et 
al., 2005; Gu et al., 2006; 
Hayward et al., 1995) 
*Zinc content is consistent with luminal epithelial levels and not cancer or benign 
prostate hyperplasia. NT=not tested; PD=preliminary data; UF=unpublished findings; 
cs=Caucasian; aa=African American 
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Table 2. Functional similarities between UGM+BPH-1 models and human PRCA  
Function 
UGM+BPH-1  
model 
Human 
Prostate 
E2-administration induces squamous metaplasia + + 
Anti-androgens stimulate squamous metaplasia + + 
Anti-androgens decrease growth of tumorigenic cells + + 
Progression states: non-tumorigenic tumorigenic state + + 
Progression states: tumorigenic into metastatic state + + 
Androgen-ablation decreased benign epithelial growth + + 
Androgen-ablation induced benign epithelial apoptosis + + 
Androgen-ablation decreased tumorigenic growth + + 
Androgen-ablation induced carcinoma apoptosis + + 
Isolated human benign, tumorigenic, metastatic cells + + 
NT=not tested; PD=preliminary data; UF=unpublished findings 
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Table 3. Comparisons of UGM+BPH-1 TRs vs human PRCA-progression 
 
Markers molecule 
Benign 
UGM+BPH-1 untreated 
Tumorigenic 
UGM+BPH-1+[T+E2] 
Parallels 
human  
Cell types  stroma epithelium stroma epithelium  
luminal cell Keratin-8,18 - + - + yes 
basal cell Keratin-14/p63 - + - +/- yes 
muscular 
stroma

 
a-actin + - + - yes 
fibroblastic 
stroma

 
vimentin +/- - + + yes 
vasculature

 Cd31 + - + - yes 
Steroid 
receptors 
AR + + + - yes 
 ER- - + - - yes 
 ER- + - + - yes 
AR regulated 
genes PSA - NT - NT 
 
NT 
 Nkx3.1

 - + - - yes 
Progression 
markers Akt - - - + 
yes 
 E-cadherin - + - - yes 
 MMP-9 low low low + yes 
 aromatase low low + + yes 
 TR-II NT + NT - yes 
 SSeCKS NT high NT low yes 
Epigenetics GSTpi - + - - yes 
Cellular 
progression:
 
  Orderly Benign Reactive Tumor/Mets 
    
yes 
 Genetics:  
LOH 
 
 
 
3p,8p, 
13p,q,17p 
  
   Tumor/Mets 
yes 
 
Proteomics-2
D/MSMS 

 
B23,G3PDH,
Lmn1 
NT low NT high yes 
yes  
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Table 3 continued. Preliminary data from Dr. William Ricke comparing UGM+BPH-1 
TRs vs human PRCA-progression 
 
 
Markers molecule 
tumorigenic 
CAF+BPH-1 untreated 
Parallels 
human  
Cell types  stroma epithelium  
luminal cell Keratin-8,18 - + yes 
basal cell Keratin-14/p63 - + yes 
muscular stroma

 a-actin + - yes 
fibroblastic stroma

 vimentin + - yes 
vasculature

 Cd31 NT - yes 
Steroid receptors AR + + yes 
 ER- - + yes 
 ER- + - yes 
AR regulated genes PSA + NT yes 
 Nkx3.1

 ? + yes 
Progression markers Akt + + 
yes 
 E-cadherin - +low yes 
 MMP-9 NT NT yes 
 aromatase NT low  
 TR-II _+ + yes 
 SSeCKS NT NT  
Epigenetics GSTpi

 NT NT  
Cellular 
progression: benign, 
tumorigenic, and 
metastatic 
transition

 
 Reactive Tumor/Met 
 
 
 
 
yes 
 
Genetics:  LOH 
 
 
 
3p,8p, 13p,q,17p 
  NT + 
yes 
 
Proteomics-2D/MS
MS 

 
B23,G3PDH,Lmn
1 
NT low yes 
yes NT= not tested; 
= factor is also a PRCA-progression marker; LOH=loss of 
heterozygosity; vasculature

, muscular stroma

, fibroblastic stroma

 are all localized in a 
manner consistent with human PRCA-progression. Detection of markers were performed 
by immunohistochemistry, gene expression arrays, rtPCR, SNP arrays, Mass Spec, 
Western blotting, and 2D gel electrophoresis. 
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Stroma in prostate carcinogenesis 
The process of prostatic carcinogenesis includes aberrations in the interactions of the 
prostatic epithelium and its local microenvironment. These changes result in reciprocal 
de-differentiation of both the emerging carcinoma cells and the prostatic smooth muscle. 
The vast majority of human prostatic cancers arise as adenocarcinomas, which are 
derived from the epithelial cells that form the glands and ducts of the prostate. As the 
carcinoma evolves, phenotypic changes and alterations in gene expression also occur in 
the adjacent stroma. These “changes” may enhance the invasive potential of the epithelial 
tumor (Grossfeld et al., 1998; Joesting et al., 2005). Chung and co-workers reported that 
co-inoculation of tumorigenic Nbf-1 fibroblasts with human PC-3 cells accelerated tumor 
growth (Chung, 1991; Chung, 1995; Chung et al., 1981). It was shown that CAFs were 
capable of stimulating carcinogenesis and inducing the progression of an initiated 
epithelium (the SV-40 immortalized BPH-1 cell line), while normal prostatic fibroblasts 
were incapable of stimulating such progression (Olumi et al., 1999). The mechanistic 
basis by which stromal-epithelial interactions enhance the process of carcinogenesis is 
still poorly understood. Many signaling pathways and molecules play important roles in 
controlling proliferation, differentiation and function in both epithelial and stromal cells. 
The cells in the tumor microenvironment supporting and nurturing the developing tumor 
include stromal fibroblasts, infiltrating immune cells, as well as blood and lymphatic 
vascular networks (Mueller and Fusenig, 2004). Tissue reaction to wound healing 
represents circumstances in which "reactive" fibroblasts with unique phenotypic 
characteristics have been described (Grinnell, 1994). These lesions were characterized by 
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the appearance of myofibroblasts. Myofibroblasts are abundant during wound contraction, 
and gradually disappear during the later stages of scar formation (Grinnell, 1994; 
Schmitt-Graff et al., 1994). These cells may arise according to specific physiological needs 
as a result of modified signals from the microenvironment (Schmitt-Graff et al., 1994). 
Similar to that seen in myofibroblasts associated with wound healing, there is abnormal 
expression of smooth muscle actin, metalloproteinases and the production of extracellular 
matrix proteins (Basset et al., 1990; Chiquet-Ehrismann et al., 1986; Knudson and 
Knudson, 1993) These differences may enhance the invasive potential of initiated epithelial 
cells and modulate the phenotype of nearby epithelial cells. A detailed understanding of 
the changes occurring within tumor stroma and to the signaling mechanisms acting 
between stroma and epithelium will allow for the rational design of therapies aimed at 
inhibiting prostate tumor growth.  
 
Stroma as a therapeutic target in prostate cancer 
 
Figure 1-6. Therapeutic strategies that have been designed or suggested to 
 target different cells in the tumor microenvironment (Joyce, 2005) 
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Traditional therapy for all epithelial malignancies, including prostate cancer, has been 
targeted at the epithelial cell which represents a moving target for treatment, in the sense that 
as the disease progresses these cells acquire progressively severe genetic changes. The 
stroma may provide a more stable target at which to direct treatment. The supporting players 
of cancer in the tumor microenvironment include stromal fibroblasts, infiltrating immune 
cells, the blood and lymphatic vascular networks and the extracellular matrix (Joyce, 2005) 
(Figure 1-6). CAF-induced tumorigenesis of BPH-1 cells is an epigenetic effect that drives 
initiated BPH-1 cells to be tumorigenic CAFs have been used to study stromal-epithelial 
interactions in prostate cancer progression (Ao et al., 2007).  There is also a growing 
evidence that DNA methylation and histone modifications play essential roles in prostate 
cancer initiation and progression (Li et al., 2005).  
 
A detailed understanding of the signaling mechanisms between stroma and epithelium 
will allow for the rational design of therapies aimed at inhibiting prostate tumor growth. 
Specific growth factors may play an important role in the stroma-epithelial interactions. 
The FGF family contains members that have been studied in regard to prostatic growth 
and branching morphogenesis. It has been shown that FGF7 and FGF10 play important 
roles during prostatic development (Thomson et al., 1997). FGF-7 is capable of imitating 
some of the effects of testosterone (Thomson et al., 1997). FGF10 (also known as 
keratinocyte growth factor-2) shows a high degree of sequence homology and shares a 
same receptor with FGF7 (Ropiquet et al., 2000). It functions as a mesenchymal paracrine 
regulator of epithelial growth in the prostate and seminal vesical, is not regulated by 
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Figure 1-8. Graft size of BPH 
senescent
 and BPH-1
NPF
. 
BPH-1+NPF BPH-1+senescent fibroblast
 
Figure 1-7. BPH-1 invaded to host kidney after 
in vivo incubation with senescent fibroblasts. 
androgens (Thomson and Cunha, 1999). The IGF family is also includes important 
mediators, which may potentially influence prostatic growth and carcinogenesis. We have 
found that TGF-ß expression is elevated in CAFs versus normal prostatic fibroblasts 
(NPFs). Also stromal-derived TGF- can regulate expression of receptors for other 
growth promoting factors expressed by CAFs.  These data indicated that the TGF-beta 
pathway may be important for stromal cells to promote adjacent epithelial tumor 
progression. Recent experiments in mice suggest that TGF- is one of the 
fibroblast-supplied factors involved in suppression of epithelial transformation and loss of 
TGF- response in fibroblasts resulted in intraepithelial neoplasia in prostate through the 
activation of paracrine hepatocyte growth factor (HGF) pathway (Bhowmick et al., 
2004a; Bhowmick et al., 2004b).  
 
Senescence and prostate cancer 
The greatest risk factor of 
developing carcinoma of the prostate 
is advanced age. Cancer is a disease 
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of uncontrolled cell proliferation caused by upregulation of oncogenic signaling and 
downregulation of tumor suppressor signaling. To counteract the uncontrolled growth, 
cells can undergo apoptosis or senescence. However, it has been proposed that in some 
conditions senescence may actually promote tumor progression, possibly by secreting 
matrix metalloproteases, growth factors and cytokines. Senescent fibroblasts were shown 
to promote tumorigenesis by immortalizing pre-malignant epithelial cells (Bavik et al., 
2006). Evidence suggested that mutations in epithelial cells alone may not be sufficient for 
the development of cancer. Malignant transformation also requires changes in the 
microenvironment in which the initiated cells can progress to full malignancy. Cellular 
senescence is the phenomenon where normal diploid differentiated cells lose the ability to 
divide. The senescence response can limit the proliferation of normal cells by telomere 
shortening. However, it was suggested that senescent cells acquire multiple phenotypic 
changes, by compromising tissue structure and function. The response may benefit 
organism in early life by preventing cancer, but could be detrimental later in life as 
senescent cells accumulate by secreting factors that damage tissue homeostasis. Dr. Peter 
Nelson‟s group in Fred Hutchinson Research Institute showed that senescent fibroblasts 
modulate neoplastic epithelial cell proliferation through paracrine mechanisms (Bavik et 
al., 2006). Their data showed that senescent fibroblasts can stimulate benign BPH-1 cells 
growth in vitro by culturing BPH-1 cells with senescent fibroblasts conditional media. 
Their results suggested that a significant component of the senescent fibroblasts‟ 
proliferative influence toward epithelium is mediated through soluble factors. The host 
environment is increasingly viewed as an important active player for tumor growth and 
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carcinogenesis. From our in vivo experiments, BPH-1 cells invaded the kidney after 
incubation with senescent fibroblasts under the renal capsule of SCID mice for two months 
(Figure 1-7). The isolated epithelial cells from BPH-1 + senescent fibroblast and 
BPH-1+NPF (which were designated as BPH-1
NPF
), showed clear difference in cell 
proliferation rate. The size of the grafts when re-grafted to kidney capsule alone showed 
clear difference (Figure 1-8). The size of BPH-1
senescent
 graft was bigger than that of 
BPH-1
NPF
. This phenomenon indicated after incubation with senescent fibroblasts the 
isolated BPH-1
senescent
 cells can grow independently under the kidney capsule.  
The somatic mutation theory of cancer suggests that carcinomas result from a single 
somatic cell that accumulates multiple DNA mutations or chromosomal alterations over 
time. The concept of a reactive stroma implies that the microenvironment is altered in 
response to epithelial change.  The reactive stroma theory suggests that stromal alterations 
are operative as primary or permissive events allowing for or magnifying a reactive 
phenotype. It was suggested that age-dependent stromal processes operate as a 
tissue-modifying field effect. A number of senescence induced mitogenic factors including 
HGF, IGF and amphiregulin (AREG) exert important effects on pre-neoplastic lesions. 
 
PTEN signaling pathway 
PTEN is one of the most frequently inactivated tumor suppressor genes in many human 
tumors, including prostate cancer. The PTEN tumor suppressor gene is located at 10q23, 
a region which has often shown deletions in prostate cancer (DeMarzo et al., 2003; 
Visakorpi, 1999; Visakorpi, 2003). The PTEN gene encodes a dual specificity 
H&E H&E 
SV-40 SV-40 
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phosphatase that regulates signal transduction pathways. It mainly functions as a lipid 
phosphatase and targets phosphatidylinositol 3,4,5-trisphosphate (PIP-3) (Maehama and 
Dixon, 1998). By dephosphorylating PIP-3, PTEN can downregulate the Akt/PKB 
signaling pathway thus promoting cell survival and inhibiting apoptosis. 
Importance of PTEN in prostate cancer and new thoughts 
The essential nature of PTEN function is evident from the early embryonic lethality of 
homozygous mutants. Pten heterozygous mutant mice develop cancers or dysplasias of 
multiple tissues including prostate (Di Cristofano et al., 2001; Di Cristofano et al., 1998; 
Suzuki et al., 1998). Loss of function of Nkx3.1 and PTEN cooperate in prostate cancer 
progression (Abate-Shen et al., 2003). In humans, PTEN undergoes Loss Of 
Heterozygosity (LOH) at relatively advanced stages in many cancers (Di Cristofano et 
al., 1998; Kim et al., 2002), suggesting that genes within this region are important for 
progression. The function of PTEN in initiating prostate cancer progression and in 
response to stroma has not been identified.  
 
Cyclin D1 in prostate tumorigenesis 
Cyclin D1 encodes the regulatory subunit of a holoenzyme that phosphorylates and 
inactivates the retinoblastoma protein and promotes progression through G1 to S phase of 
the cell cycle (Fu et al., 2004; Petty et al., 2003). Overexpression of cyclin D1 plays 
important roles in the development of a subset of human cancers including breast cancer, 
colon cancer and melanoma (Fu et al., 2004; Polsky and Cordon-Cardo, 2003). In human 
cancers, overexpression of cyclin D1 is one of the most commonly observed alterations 
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(Fu et al., 2004). Increased cyclin D1 abundance occurs relatively early during 
tumorigenesis. However, the role of cyclin D1 in prostate cancer has not been previously 
studied in detail. Studies have shown that mouse prostate epithelial cells have elevated 
cyclin D1 expression as they enter the cell cycle (Day et al., 2002). Some studies have 
suggested that human prostate carcinoma cell lines frequently express relatively high 
levels of cyclin D1 protein, even though this gene is not amplified in these cell lines (Day 
et al., 2002). This situation is analogous to that seen in a subset of human breast cancer 
cell lines and tumors. The functional effects of the increased expression of cyclin D1 in 
prostate carcinoma cells remain to be determined.  Immunostaining studies indicated 
that primary prostate carcinoma samples displayed moderate or strong expression of 
cyclin D1 protein. Overexpression of cyclin D1 can increase tumorigenicity of LNCaP 
cell lines (Chen et al., 1998). It has been reported that cyclin D1 overexpression might be 
related to the evolution of androgen-independent disease in prostate cancer (Chen et al., 
1998). However, several studies have also suggested that amplification and/or 
overexpression of cyclin D1 is not a common event in either primary and tumor-derived 
prostate cell lines (Chen et al., 1998). This calls into question the relevance of the in vitro 
studies and makes the point that while something may be possible it is not necessarily 
relevant. Since stromal environment plays an important role in tumor progression and no 
study has shown the role of cyclin D1 in the stroma, questions over the role of cyclin D1 
in prostate cancer progression has driven our attention to study the consequences of 
cyclin D1 over expression in both epithelial and stromal tissues.  
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Prostate cancer research has been hindered by the lack of well established, characterized, 
immortalized benign prostatic epithelial cells lines and human models. In this project, 
we have used a few benign prostatic epithelial cell lines in an effort to build new in vivo 
models of human prostate cancer progression. We have already successfully built a new 
model of human prostate cancer progression by overexpression cMyc oncogene. The 
aim of this project to build less aggressive models that represent distinct grades of 
disease by manipulating different genes. Taken together, important oncogenes (such as 
cyclin D1) and tumor suppressor genes (such as PTEN) are expected to be the essential 
players in the stromal-epithelial interaction in prostate cancer progression. A detail 
understanding of the mechanism of this interaction by modifying either the epithelial or 
the stromal compartments will elucidate new therapeutic targets. The central hypothesis 
of this proposal is that stromal-epithelial interactions play a crucial role in prostate 
cancer progression and are a potential therapeutic target.  
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CHAPTER II 
 
TISSUE-SPECIFIC CONSUQUENCES OF CYCLIN D1 OVEREXPRESSION IN 
PROSTATE CANCER PROGRESSION 
Introduction 
Prostate development is controlled by steroid hormones that induce and maintain a 
complex cross talk between the stromal and epithelial cells (Cunha and Young, 1992). 
The result of this intercellular communication depends upon the context and 
differentiation status of the cell type being stimulated (Hayward and Cunha, 2000; 
Hayward et al., 1998). The process of prostatic carcinogenesis includes aberrations in the 
interactions of the prostatic epithelium and its local microenvironment resulting in 
reciprocal de-differentiation of both the emerging carcinoma cells and the prostatic 
smooth muscle.  
 
The vast majority of human prostatic cancers arise as adenocarcinomas which, by 
definition, are derived from the epithelial cells that form the glands and ducts of the 
prostate. As the carcinoma evolves, phenotypic changes and alterations in gene 
expression also occur in the adjacent stroma. These “changes” may enhance the invasive 
potential of the epithelial tumor (Grossfeld et al., 1998; Joesting et al., 2005). Chung and 
co-workers reported that co-inoculation of tumorigenic Nbf-1 fibroblasts with human 
PC-3 cells accelerated tumor growth (Chung, 1991; Chung, 1995; Chung et al., 1991). 
More recently it was shown that human CAFs were capable of stimulating carcinogenesis 
and inducing the progression of an initiated epithelium (the SV-40 immortalized BPH-1 
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cell line), while normal prostatic fibroblasts were incapable of stimulating such 
progression (Olumi et al., 1999). The mechanistic basis by which stromal-epithelial 
interactions enhance the process of carcinogenesis is still poorly understood.  
 
The cells in the tumor microenvironment supporting and nurturing the developing tumor 
include stromal fibroblasts, infiltrating immune cells, blood and lymphatic vascular 
networks (Mueller and Fusenig, 2004; Tuxhorn et al., 2001). A detailed understanding of 
the changes occurring within tumor stroma and to the signaling mechanisms acting 
between stroma and epithelium will allow for the rational design of therapies aimed at 
inhibiting prostate tumor growth.  
 
Cyclin D1 encodes the regulatory subunit of a holoenzyme that phosphorylates and 
inactivates the retinoblastoma protein and promotes progression through G1 to S phase of 
the cell cycle (Fu et al., 2004; Petty et al., 2003). Overexpression of cyclin D1 plays 
important roles in the development of human cancers including breast, colon and 
melanoma (Bartkova et al., 1995; Hunter and Pines, 1994; Polsky and Cordon-Cardo, 
2003; Roy and Thompson, 2006; Sherr et al., 1992). Increased cyclin D1 expression 
occurs relatively early during tumorigenesis, however, its role in prostate cancer is not 
well understood. Studies have shown that mouse prostatic normal and Rb-/- epithelial 
cells have elevated cyclin D1 expression as they enter the cell cycle (Day et al., 2002). 
Human prostate carcinoma cell lines frequently express elevated levels of cyclin D1 
protein, although the gene is not amplified in these cells (Day et al., 2002). This situation 
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is analogous to that seen in a subset of human breast cancer cell lines and tumors (Arnold 
and Papanikolaou, 2005; Caldon et al., 2006). Overexpression of cyclin D1 can increase 
tumorigenicity of LNCaP cell lines. Additionally, androgen ablation has a smaller 
inhibitory effect on tumors formed by cyclin D1 overexpressing LNCaP cells compared 
with tumors formed by parental LNCaP cells, which regress after castration. This 
phenomenon suggests that cyclin D1 overexpression might be related to the evolution of 
androgen-independent prostate cancer (Chen et al., 1998). Immunostaining studies 
indicated that primary prostate carcinoma samples displayed moderate or strong 
expression of cyclin D1 protein in the epithelial compartment compared to normal 
epithelium. Little is known about the role of cyclin D1 in the stromal compartment of 
tumors, especially in adenocarcinomas. One study of cyclin D1 expression in esophageal 
carcinomas indicated that cyclin D1 is strongly expressed in stromal fibroblasts (Pera et 
al., 2001). 
 
In this chapter we examined the consequences of targeted regulation of cyclin D1 
expression in epithelial or stromal cells in order to investigate the effects of cyclin D1 in 
prostate cancer progression. 
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Materials and Methods 
Cells 
BPH-1 (a non-tumorigenic prostate epithelial cell), and its tumorigenic derivatives 
BPH
CAFTD1
 and BPH
CAFTD2
 were from our own stocks. DU145, LNCaP and PC3 cells 
were obtained from ATCC (Rockville, MD, USA). NPFs, BPH fibroblasts and CAFs 
were isolated and bioassayed as previously described (Olumi et al., 1999). Prostatic 
Epithelial cell (PrE)1 cells were isolated from human benign prostate tissue. 957E/hTERT 
cells were generously supplied by Dr. John Issacs (Johns Hopkins). PrE3 cells were 
kindly provided by Dr. Dean Tang (M. D. Anderson). BPH-1
C7-cyclin D1
, BPH-1
C7-
, 
BPH-1
NPF
, NPF
cyclin D1
 and BPH-1
NPF-cyclin D1
 cells were generated as described below. All 
of the epithelial cells were maintained in RPMI 1640 (Gibco, Carlsbad, CA) with 1% 
antibiotic/antimycotic (Life Technologies, Grand Island, NY) and 5% Cosmic Calf Serum 
(CCS) (HyClone, Logan, Utah). All of the stromal cells were maintained in the same 
condition except 5% Fetal Bovine Serum (FBS) (Atlanta Biologicals, Atlanta, GA) was 
used. 
 
Construction of cyclin D1 expression vector 
The plasmid C7-cyclin D1 was constructed using the LZRS-EGFP backbone (Nolan 
Laboratory, Stanford University, CA). The CMV promoter was cut from pIRES-EGFP 
(Clontech, Palo Alto, CA) as a BglII/BamHI fragment. The fragment was then ligated into 
the BamHI site of the LZRS-EGFP backbone to produce C7-. The human cyclin D1 
cDNA clone was obtained from ATCC (Rockville, MD) and amplified by PCR using a 5’ 
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primer specific to translational start site and a 3’ primer containing an XhoI restriction site 
and the consensus sequence for the translational stop site. After PCR amplification, the 
product was gel purified, and cloned into pGem T-Easy (Promega, Madison, WI). 
Following DNA sequence verification, the cyclin D1 coding region was cut using 
EcoRI/XhoI and sub-cloned into the EcoRI/XhoI sites of pLZRS-EGFP to obtain 
C7-cyclin D1 construct. 
 
Generation of a stable cyclin D1 overexpressing BPH-1 cell line 
Viral particles were prepared as previously described and used to infect BPH-1 cells 
(Williams et al., 2005). Fresh virus was placed onto target cells every 24 hours until green 
fluorescent protein expression was observed. Cell sorting was performed to select the 
GFP-expressing BPH-1 cells. Two stable cell lines were generated: C7-cyclin D1 
overexpressing BPH-1 cell line and C7- control BPH-1 cell line which were designated as 
BPH-1
C7-cyclin D1 
and BPH-1
C7-
 respectively. 
 
Generation of NPF
cyclin D1
 cells 
Human prostatic cells were prepared as described previously (Williams et al., 2005). 
Cyclin D1 virus was generated using phoenix A cells, and the prostatic cells were infected 
as described (Williams et al., 2005). After 1 week of successive rounds of infection, some 
cells expressed EGFP when monitored by fluorescence microscopy. Differential 
trypsinization was used to separate fibroblasts from the epithelial cells. The resulting 
colonies were characterized by phenotype and their nature confirmed using 
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immunocytochemical staining against keratin and vimentin. After 12 passages, 
EGFP-expressing cells self sorted as all unstained cells became senescent and died. 
Western blotting analysis 
Cell lysates were prepared and western blotting was performed as previously described 
(Williams et al., 2005). Membranes were incubated with mouse monoclonal antibody to 
cyclin D1 (BD Biosciences Pharmingen, San Jose, CA, 1:1,000 dilution) or -tubulin 
(Santa Cruz Biotechnology, Santa Cruz, CA, 1:1,000 dilution) overnight, washed with 
PBS-Tween 20 for 1 hour, and incubated with horseradish-Peroxidase linked anti-mouse 
or anti-rabbit secondary antibody (Amersham Biosciences, Piscataway, NJ, 1:1,000 
dilution) for 1 hour. Bound antibodies were visualized using enhanced 
chemiluminescence western blotting detection reagents (Amersham Bioscences). Cyclin 
D1 expression levels were normalized to -actin and quantitated using Image J software 
from the NIH (http://rsb.info.nil.gov/ij/). 
 
Growth curves 
BPH-1
C7-
 and BPH-1
C7cyclin D1
 cells were plated in a 24-well plate (1000 cells/well) in 
RPMI 1640 medium supplemented with 5% CCS. After the cells had attached overnight, 
300 µl of Cell Titer 96 Aqueous One Solution (Promega, Madison, WI) was added at 
indicated times (1, 2, 3, 4, and 5 days) to each well and the absorbance was measured at 
490 nm after 3 hours of incubation at 37
o
C. Experiments were performed in triplicate. 
 
Wound healing assays 
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Confluent monolayers of BPH-1
C7-
 and BPH-1
C7-cyclin D1
 cells were grown in 6 well 
plates. An even line of cells was displaced by scratching through the layer using a pipet 
tip. Specific points on the wounds were identified and marked. These open areas were 
then inspected microscopically over time as the cells move in and fill the damaged area. 
Wounds were imaged at 0, 3, 6, and 8 hours post wounding and the cell migration rate 
into the wound was calculated. Experiments were performed in triplicate. 
 
Transwell migration assay 
One hundred thousand BPH-1
C7-
 or BPH-1
C7-cyclin D1
 cells were plated on top of the 8µm 
pore polycarbonate culture inserts (Becton Dickinson labware, Franklin Lakes, NJ),  
which were situated in wells of a 24-well culture plate and immersed in RPMI 1640 
medium supplemented with 5% CCS. The cells were incubated at 37ºC for 12 hours. The 
cells on the upper surface of the inserts were removed using cotton swabs and those 
which had migrated to the bottom side, were fixed with 11% glutaraldehyde (Sigma, St. 
Louis, MO) for 20 minutes, stained with 0.1% crystal violet (Sigma) for 20 minutes. 
Inserts were then washed with water 3 times. The number of cells that had migrated was 
counted using a microscope. The filters were viewed under bright-field optics to count 
stained cells in eight fields (with a 20X objective) for the two types of cells. The mean 
number of cells per field was determined, and results from at least three experiments were 
expressed as the mean relative cell migration ± Standard Deviation (SD), with that of 
BPH-1
C7-cells set at 1. 
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Boyden chamber assay 
Polycarbonate culture inserts with 8 m-pores were coated with 20 l 2.5 mg/ml matrigel 
(BD Biosciences, Bedford, MA). After the gel solidified, the chambers were equilibrated 
with RPMI 1640 with 5% CCS for 2 hours in a humidified tissue culture incubator at 
37°C with 5% CO2 atmosphere. More media were then added to the lower compartment, 
and 100k BPH-1
C7-
 and BPH-1
C7-cyclinD1 
cells were seeded in the upper compartment of 
the chamber. Each cell group was plated in 3 duplicate wells. After 12 hours incubation, 
the matrigel was removed using a cotton swab. The number of cells that had migrated to 
the lower sides of the membrane was then determined as described for the transwell 
migration assay. 
 
Tissue recombination and xenografting 
One hundred thousand epithelial cells and 300k stromal cells were recombined to make 
the BPH-1
C7-
+ rUGM, BPH-1
C7-cyclinD1
 + rUGM, BPH-1 + NPF and BPH-1 + NPF
cyclin 
D1 
tissue recombinants as previously described (Hayward et al., 1999). After incubating 
overnight at 37
o
C, the tissue recombinants were grafted under the kidney capsule of adult 
male SCID mice (Harlan, Indianapolis, IN). All the experiments were repeated 6 times.  
Mice were sacrificed after four weeks and grafts were harvested, fixed and imbedded. 
 
Immunohistochemical staining 
Immunohistochemical staining was performed following a protocol that was described 
previously (Williams et al., 2005). Tissue slides were incubated with the primary 
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antibody against SV40 (Santa Cruz Biotechnology, Santa Cruz, CA, 1:1000 dilution) 
overnight. The polyclonal rabbit immunoglobulins/biotinylated anti-mouse secondary 
antibody (DAKO, Carpentiria, CA) was incubated for 60 minutes after the slides were 
washed with PBS buffer for 1 hour. After washing the slides in PBS extensively, slides 
were incubated in ABC-HRP complex (Vector Laboratories) for 30 minutes. Bound 
antibodies were then visualized by incubation with 3,3’ diaminobenzidine 
tetrahydrochloride (liquid DAB, DAKO). Slides were then rinsed extensively in tap 
water, counterstained with hematoxylin, and mounted.  
 
Isolation of cell strains and regrafting 
BPH-1
NPF
 and BPH-1
NPF-cyclin D1
 cells were isolated and selected with 50µg/ml G418 
(Clontech, Palo Alto, CA) from BPH-1 + NPF and BPH-1 + NPF
cyclin D1
 grafts, and 
regrafted without stromal cells to SCID mice as previously described (Hayward et al., 
1999). Four to fourteen weeks after grafting, the hosts were sacrificed. The harvested 
grafts were removed from the kidney and formalin-fixed for immunohistochemical 
analysis.  
 
Cell Cycle Analysis 
BPH-1
NPF
 cells and BPH-1
NPF-cyclin D1 
cells were harvested from monolayer culture. The 
cell pellets were washed and resuspended in PBS and fixed with 80% ETOH with 
vortexing. Cells were then pelleted and resuspended with PBS containing 1% CCS for 
cell counting after storing at -20
0
C for 4 hours. 100,000 cells were resuspended in 
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Propidium Iodide (PI) / RNase / 1% CCS / PBS. PI was used to stain double-stranded 
nucleic acids stoichiometrically. Cells were treated with RNase A in order to stain only 
the DNA. Cell cycle distribution was analyzed on the flow cytometer after at least 30 
minutes.  
 
Microarray analysis 
We collaborated with Dr. Peter Nelson in Fred Hutchinson Research institute to perform 
the microarray analysis. Cells were made in our laboratory and the analysis was done in 
Dr. Peter Nelson’s laboratory. NPFcyclin D1 cells were generated from NPFs, which were 
isolated from two different patient samples; CAFs were isolated from two different 
patient samples as well. RNA was isolated from NPFs, CAFs, and NPF
cyclin D1
 cells using 
total RNA isolation kit (Qiagen). Custom spotted cDNA microarrays were constructed as 
previously described (True et al., 2006) using a non-redundant set of 6,700 
prostate-derived cDNA clones identified from the Prostate Expression Data Base 
(PEDB), a public sequence repository of expressed sequence tag data derived from 
human prostate cDNA libraries. Total RNA was amplified through one round of linear 
amplification using the MessageAmp aRNA kit (Ambion, Austin, TX). Sample quality 
and quantification was assessed by agarose gel electrophoresis and absorbance at A260. 
Cy3 and Cy5 labeled cDNA probes were made from 4 µg of amplified RNA. Two 
NPF
cyclin D1
 and two CAF samples (labeled with Cy3) were hybridized head-to-head with 
an NPF control sample labeled with Cy5. Probes were hybridized competitively to 
microarrays under a coverslip for 16 h at 63°C. Fluorescent array images were collected 
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for both Cy3 and Cy5 by using a GenePix 4000B fluorescent scanner, and image intensity 
data were gridded and extracted using GenePix Pro 4.1 software. Differences in gene 
expression between NPF
cyclin D1
/NPF and CAF/NPF groups were determined using a 
two-sample t-test with Significance Analysis of Microarrays (SAM) software 
(http://www-stat.stanford.edu/_tibs/SAM/) with a False Discovery Rate (FDR) of ≤ 10% 
considered significant.  Similarities in gene expression between NPF 
cyclin D1
/NPF and 
CAF/NPF groups were determined using a one-sample t-test in SAM with an FDR of ≤ 
0.1% considered significant. These results were reduced to unique genes by eliminating 
all but the highest scoring clones for each gene.  A Pearson correlation coefficient was 
calculated in Excel to assess the strength of the linear relationship between NPF
cyclin 
D1
/NPF and CAF/NPF average log2 ratios. 
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Results 
Cyclin D1 expression levels are elevated in malignant human prostatic epithelial cell 
lines 
Cyclin D1 expression was examined by Western blotting in the prostate cancer cell lines, 
DU145, LNCaP, BPH
CAFTD1
 and BPH
CAFTD2
 and in a subset of non-tumorigenic prostatic 
cells, PrE1, 957E/hTERT (Dalrymple et al., 2005; Yasunaga et al., 2001), PrE3 and 
BPH-1 cell line. Cyclin D1 expression was found to be higher in all of the cancer cells as 
compared to the non-tumorigenic prostatic cells. A representative Western Blot is shown 
in Figure 2-1.Primary epithelial cells had the lowest cyclin D1 expression. The SV40 
T-antigen immortalized BPH-1 cells had higher cyclin D1 expression compared with PrE, 
957/hTERT and PrE, but lower expression level than that in malignant cell lines. These 
data crudely correlate cyclin D1 with tumorigenicity but, as with similar correlations seen 
in patient samples, do not address whether cyclin D1 overexpression is a cause or an 
effect of malignant change. In order to address this question we tested the consequences 
of overexpressing cyclin D1 in non-tumorigenic prostatic epithelial cells.  
 
Cyclin D1 overexpression in BPH-1 cells can increase cell proliferation rate, 
migration and invasive ability in vitro 
Western blotting showed that the BPH-1
cyclin D1 
cells have a 34 fold elevation in cyclin D1 
expression compared with control BPH-1
C7-
 cells (Figure 2-2, A). BPH-1
C7-cyclin D1
 cells 
showed enhanced motile ability in wound healing, transwell migration and Boyden 
chamber assays. Wound healing assays showed that BPH-1
C7-cyclin D1
 cells were 
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significantly more motile than BPH-1
C7-
 cells. This difference was clear after 3 hours and 
was very marked after 8 hours (Student’s t-test, P<0.001) (Figure 2-2, B). In a transwell 
migration study, the BPH-1
C7-cyclin D1
 cells migrated through the uncoated Boyden 
chambers to the underside of the insert in greater numbers in a 12 hour response to 
conditional medium containing 1% CCS in the lower chamber than BPH-1
C7-
 cells 
(Student’s t-test, P<0.05) (Figure 2-2, C). These data confirmed the elevated motility of 
BPH-1
C7-cycin D1
 cells, as seen in the wound healing assay. An invasion assay, in which the 
inside chamber was coated with matrigel to mimic the in vivo extracellular matrix, 
demonstrated that BPH-1
C7-cyclin D1
 cells had significantly increased invasive activity in 
vitro (Student’s t-test, P<0.01) (Figure 2-2, D). We used an MTT assay to assess the effect 
of cyclin D1 overexpression on the growth rate of BPH-1 cells. Our results showed that the 
cyclin D1 overexpressing cells proliferated faster than control cells. The difference was 
observed even after 24 hours incubation (Figure 2-2, E). Collectively the assays showed 
that when cyclin D1 is forcibly overexpressed, BPH-1 cells acquired an enhanced 
proliferation rate, motility and invasive ability in vitro.  
 
Cyclin D1 overexpressing BPH-1 cells are not tumorigenic in tissue recombinants 
with rUGM 
To determine whether cyclin D1 could exert a tumorigenic effect on prostate cells in vivo, 
100k BPH-1
C7-cyclin D1 
cells or control cells were recombined with 300k rUGM and grafted 
under the kidney capsule of SCID mice. The grafts were harvested after 4, 8, 12 and 16 
weeks. The results showed that BPH-1
C7-cyclin D1
 cells formed significantly larger and 
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more vascularized grafts under the induction of rUGM, compared with BPH-1
C7- 
cells. 
An example of the gross morphology of grafts at 8 weeks is shown in Figure 2-3, A. These 
results are consistent with our in vitro experiments, which showed that BPH-1
C7-cyclinD1
 
cells proliferate faster than controls. Histologically, both experimental and control grafts 
exhibited the formation of solid epithelial cords surrounded by a muscular stroma. SV-40 
T-antigen staining confirmed the origin of BPH-1 cells in both control and cyclin D1 
overexpressing groups and showed that there were sharp delineations from the host 
kidney (denoted as k in the figure) with no sign of invasion (Figure 2-3 B and C). It was 
noteworthy that a clear layer of stromal cells was always seen between the graft and host 
kidney under both control and test conditions. In the control grafts few epithelial cells 
were phospho histone H3 positive (indicating low proliferation rates). However, there 
were significantly more histone H3 positive cells in BPH-1
cyclin D1 cords (Student’s t-test, 
P<0.01, data not shown). These data indicated that BPH-1
cyclin D1 
cells proliferated much 
faster than control cells (Figure 2-3, B and C). To assess whether cyclin D1 can transform 
BPH-1 cells in a longer period of time in vivo, we sacrificed mice every month for up to 4 
months. The histological appearance of the grafts at 4 months was similar to the earlier 
grafts with solid cord structures and no invasion of the kidney (date not shown). Therefore, 
while cyclin D1 can increase BPH-1 cell motility and promote cell proliferation in vitro, 
overexpression of the gene did not induce BPH-1 cells to undergo malignant 
transformation with associated invasion.  
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NPF
cyclin D1
 cells have increased life span compared with NPFs and CAF cells have 
upregulated cyclin D1 expression 
Since the stroma is viewed as an important active contributor to tumor growth, and in order 
to understand whether cyclin D1 performs different functions in stromal and epithelial 
tissues, we generated NPF
cyclin D1
 cells by overexpressing cyclin D1 in primary cultures of 
normal prostate stromal cells. To investigate whether the cyclin D1 overexpressing 
fibroblasts have an increased life span compared to control or non-infected cells, we 
passaged the cell mixtures 12 times. The uninfected cells underwent spontaneous 
senescence and died within 12 passages. The EGFP-expressing cells still looked healthy 
and grew well after 11 more passages (total 23 passages-Figure 2-3, A). Western blot 
analysis demonstrated that EGFP positive cells also overexpressed cyclin D1 (Figure 2-4, 
B). This result indicated that NPFs acquired a prolonged life span as a consequence of 
upregulated cyclin D1.  
 
It has previously been shown that CAF cells can induce BPH-1 cells to undergo malignant 
transformation while normal prostatic fibroblasts cannot (Olumi et al., 1999). Cyclin D1 
has been shown to be strongly expressed in stromal fibroblasts in carcinoma and 
adenocarcinoma (Pera et al., 2001). We were interested to determine whether human 
prostatic CAFs have elevated cyclin D1 expression and if so whether CAFs and NPF
cyclin D1 
cells share common functional sequelae. Therefore, we examined the expression level of 
cyclin D1 in NPFs, BPH fibroblasts and CAF cells. These experiments showed that CAFs 
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expressed a much higher level of cyclin D1 protein than either NPFs or fibroblasts isolated 
from BPH patients (Figure 3B).  
 
NPF
cyclin D1
 cells elicit CAF-like effects promoting tumorigenesis 
To investigate the in vivo consequences of overexpression of cyclin D1 in NPFs, 100k 
BPH-1 cells were recombined either with 300k NPF
cyclin D1
 or NPF cells. Grafts were 
harvested after one month. Tissue recombinants composed of BPH-1 + NPF
cyclin D1 
exhibited moderate growth, in contrast, consistent with previously published data, control 
recombinants composed of BPH-1 + NPFs demonstrated minimal growth. Control grafts of 
NPF and NPF
cyclin D1
were likewise small and flattened (Figure 2-5, A a and b). Comparison 
between the volume of the control and test recombinants showed that the test samples were 
significantly larger (Student’s t-test, P<0.01). The histological appearance of the BPH-1 + 
NPF
C7-cyclin D1
 grafts, as assessed by H & E staining, resembled a poorly differentiated 
carcinoma with areas of squamous differentiation (Figure 2-5 B,a and b). Instead of 
forming solid cord structures, some epithelium fused to form large nests with keratinization 
and a broad pushing margin against the host kidney (Figure 2-5, B a and b). Tumors also 
contained irregular epithelial cords intermingled within a fibrous stroma (Figure 2-5, B e 
and f-right arrow). In other areas, single epithelial cells were intermixed with fibrous 
stroma (Figure 2-5, B c-arrow and f-left arrow). SV-40 T antigen staining confirmed the 
origin of the epithelial component of the tumors as being from the BPH-1 cells (Figure 2-5, 
B c and f). E-cadherin expression was patchy, with positive expression in cell-cell junctions 
in some areas, but weak or absent in many areas (Figure 2-5, B d). The histology of 
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recombinants of BPH-1 + NPF
cyclin D1 
was similar to that previously described for BPH-1 + 
CAFs recombinants (Dalrymple et al., 2005; Olumi et al., 1999), although the overall 
tumor size was smaller. After 5 months of incubation in the kidney capsule, BPH-1 cells 
formed larger tumors with clear kidney invasion (Figure 2-5, B g and i). Small kidney 
tubes intermingled with tumor cells (Figure 2-5, B g-arrow and h-arrows) and there were 
no clear margins between the kidney and grafts.  
 
In contrast to the malignant histological appearance of the BPH-1 + NPF
cyclin D1
 
recombinants, the BPH-1 + NPF recombinants appeared benign and, as previously 
described, the bulk of the grafts were composed of stromal cells. Occasional small 
epithelial cords are found (Figure 2-5, B k and l).  This confirmed previous observations 
that stromal cells from normal peripheral zone recombined with BPH-1 cells produced 
benign or no visible grafts (Barclay et al., 2005; Olumi et al., 1999). To examine if NPF
 
cyclin D1
 cells are tumorigenic, we grafted either NPF or NPF
 cyclin D1
 cells alone to SCID 
mice. Both control groups formed flattened grafts (Figure 2-5, A c and d). H & E staining 
showed that both grafts were present as a thin layer of fibrous tissue (data not shown).  
 
Epithelial cells isolated from BPH-1 + NPF
cyclin D1
 grafts (BPH-1
NPF-cyclin D1
) are 
tumorigenic 
After cell culture and G418 selection, two cells strains were derived from BPH-1 + NPF 
and BPH-1 + NPF
cyclin D1 
grafts, designated BPH-1
NPF
 and BPH-1
NPF-cyclin D1
. The two 
strains were grafted in collagen gels beneath the renal capsule of male SCID mice. 
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Grossly, after 3 months, the BPH-1
NPF-cyclin D1
 cells formed significantly larger grafts than 
the control group (Figure 2-6, A-right). The control group formed small flattened grafts 
(Figure 2-6, A-left). Histologically, the BPH-1
NPF
 cells grew to form occasional small 
cords, which were SV-40 positive, similar to the grafts previously reported for BPH1 
cells grafted alone (Figure 2-6, B). The BPH-1
NPF-cyclin D1
 cells, in contrast, formed large 
fused nests generally with a broad pushing margin to the host kidney (Figure 5C,a-arrow).  
Many smaller nests with irregular shapes were scattered throughout the tumor and 
intermingled with stroma (Figure 2-6, C, d and e). Some infiltrative areas recapitulated 
prostatic carcinoma (Figure 2-6, C b-arrow). Cells contained a foamy cytoplasm and their 
borders were indistinct (Figure 2-6, C c-arrow) . Minimally invasive growth was found in 
some areas (Figure 2-6, C f). Tumors continued to express SV-40T-antigen confirming 
the BPH-1 origin of the malignant epithelium. 
 
DNA flow cytometry analysis demonstrated that stromal cyclin D1 caused a shift of the 
cell cycle distribution of BPH-1
 NPF-cyclin D1
 cells. An abnormal wider peak which contains 
55% of the cell population is located close to where the G2/M peak (which has twice the 
normal copies of DNA) is supposed to be, but its position is below the G2/M peak 
position. It was reported that a wide peak may represent two populations of cells with 
different quantities of DNA (Seidman et al., 1992). Given that the original BPH-1 
population has previously been described to have an abnormal chromosomal make up and 
further that this can be altered by exposure to cancer stroma it is possible that 
BPH-1
NPF-cyclin D1 
cells become hyperdiploid or nearly tetraploid, and the hyperdiploid cell 
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population mixed with the tetraploid G2/M population to produce this abnormal peak. A 
large proportion (23.1%) of BPH-1
NPF-cyclin D1
 cells also appear to be polyploid with 
varying but high DNA content. In marked contrast, only 0.9% of BPH-1
NPF
 cells were 
found to be polyploid and BPH-1
NPF
 cells showed a normal distribution of cell 
populations with 64% cells in the G1 phase of cell cycle (Figure 2-6, D).   
 
Gene expression profiles were highly concordant between CAFs and NPF
cyclin D1
 cells 
This data were received from Dr. Peter Nelson lab. The gene expression patterns of NPFs, 
CAFs and NPF
cyclin D1
 cells were compared by cDNA microarray analysis (GEO 
submission (GSE6936) [NCBI tracking system #15248638]. NPF
cyclin D1
 cells and CAFs 
showed a high level of gene expression correlations when compared to NPFs (Pearson r = 
0.65 across all 5652 clones returning data in all 4 samples.) A one-sample t-test in SAM 
identified 118 unique genes up-regulated and 51 unique genes down-regulated (q-value ≤ 
0.1%) commonly expressed between NPF
cyclin D1
 cells and CAFs when compared with 
NPFs. (Figure 2-7 A and B). Relatively few significant differences in transcript 
abundance measurements between NPF
cyclin D1
 cells and CAFs were identified:  a 
two-sample t-test in SAM identified 6 unique genes up-regulated and 20 unique genes 
down-regulated (q-value ≤ 10%) in CAFs when compared with cyclin D1 overexpressing 
fibroblasts (Figure 2-7 C).  
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Figure 2-1. Cyclin D1 protein expression in a panel of human prostatic epithelial cells. 
Western blotting was performed to examine cyclin D1 protein expression levels in 
malignant (BPH-1
CAFTD1
, BPH-1
CAFTD2
, DU145, LNCaP and PC3) and non-tumorigenic 
(PrE1, 957E/hTERT, PrE3 and BPH-1) prostatic epithelial cell lines. The PrE1, 
957/hTERT, PrE3 cells had the lowest cyclin D1 expression compared with other 
transformed prostate cell lines. BPH-1 cells had moderate level of cyclin D1 expression.  
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Figure 2-2. In vitro comparison of BPH-1
C7-
 and BPH-1
C7-cyclin D1
 cells.  
(A) In order to examine the role of cyclin D1 in prostate cancer progression, C7- (control 
- BPH-1
C7-
) and cyclin D1 overexpressing (BPH-1
C7-cyclin D1
) BPH-1 cell lines were 
generated by stable retroviral infection. Cyclin D1 overexpression in BPH-1
C7-cyclin D1
 was 
confirmed by western blotting and band intensity quantitated. 
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Figure 2-2 (B). Wound healing assay. BPH-1
C7-cyclin D1
 closed wounds in the confluent 
monolayer significantly faster than BPH-1
C7-
 cells. Images (left) and quantitation (right) 
shown. Student’s t-test, P<0.001.  
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Figure 2-2 (C). Transwell migration study and invasion assay. BPH-1
C7-cyclin D1
 migrated 
through the uncoated Boyden chamber significantly faster than BPH-1
C7-
 Representative 
phase-contrast optical photomicrographs after overnight culture shown (a, above) and 
quantitated (a, bottom). Student’s t-test, P<0.05. BPH-1C7-cyclin D1 cells had increased 
invasive ability in a Matrigel coated Boyden chamber invasion assay compared to 
BPH-1
C7-Representative phase-contrast optical photomicrographs after overnight 
culture shown (b, above) and quantitated (b, bottom). Student’s t-test, P<0.01. 
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Figure 2-2 (D). Proliferation assay. Cyclin D1 overexpression promoted BPH-1 cell 
proliferation significantly over control growth rate. (Student’s t-test, P<0.001). 
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Figure 2-3. Overexpression of cyclin D1 in epithelium was insufficient to induce malignant 
transformation in BPH-1 cells as determined by in vivo assays.  
(A) BPH-1
C7-cyclin D1
 cells were not tumorigenic under the influence of the inductive rat 
UGM in the tissue recombination model. Gross morphology of 2 months grafts of 
BPH-1
C7-
 + UGM (left) and BPH-1
C7-cyclin D1
 + UGM (right). The volume of grafts 
containing BPH-1
C7-cyclin D1
 was significantly larger than controls. Student’s t-test, P< 0.01.  
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Figure 2-3 (B). H & E staining of BPH-1
C7-
 + UGM grafts showed that the recombinants 
formed solid cord structures with no sign of invasion to the host kidney. SV40 T-antigen 
staining confirmed the cell origin of the epithelium. Phospho histone H3 staining identified 
few positive cells in the solid cords. Higher magnification pictures were shown in bottom. 
Scale bar equals 50 µm. 
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Figure 2-3(C). H & E and SV-40 T antigen staining of BPH-1
C7-cyclin D1
 + UGM grafts. 
Histology is similar to that seen in the control groups. The basement membrane between 
kidney and graft was intact and there was no sign of invasion into the host kidney was seen. 
Phospho histone H3 staining identified significantly more positive cells in the solid cords 
compared in B. Higher magnification pictures were shown in bottom. Scale bar equals 50 
µm. 
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Figure 2-4. Expression of cyclin D1 in human prostatic fibroblasts. (A) NPF
cyclin D1
 cells 
have increased life span compared with NPF cells. Control cells were all dead within 12 
passages. The NPF
cyclin D1
 cells appeared healthy after 23 passages (passage number shown 
adjacent to illustration) post-infection by C7-cyclin D1 overexpressing retroviral vector 
(total 23 passages). (B) Western blotting results confirmed cyclin D1 was overexpressed in 
NPF
cyclin D1
 cells. Human prostatic carcinoma-associated fibroblasts (CAF) cells also 
expressed elevated levels of cyclin D1 protein as compared to NPF or to BPH-derived 
fibroblasts. 
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Figure 2-5. Effects of NPF
cyclin D1
 cells on BPH-1 epithelium in vivo.(A) Gross morphology 
of one month grafts of tissue recombinants composed of BPH-1 + NPF(a), BPH-1 + 
NPF
cyclin D1
 cells (b), NPF alone (c) and NPF
cyclin D1
 alone (d). The graft volume of BPH-1 + 
NPF
cyclin D1
 was significantly larger than that of BPH-1 + NPF. Student’s t-test, P<0.001 
(right). 
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Figure 2-5 (B). Staining of BPH-1 + NPF
cyclin D1
 recombinants revealed organization 
resembling a poorly differentiated carcinoma. Some epithelium fused to form large nests 
(a, b) with keratinization and a broad pushing margin to kidney (a, arrow). Tumors 
contained irregular epithelial cords and epithelial cells intermingled within a fibrous stroma 
(c, e and f-right arrow). Single epithelial cells were intermixed with fibrous stroma in other 
areas (c-arrow and f-left arrow).  Immunohistochemical localization of SV-40 T antigen 
confirmed the origin of the tumors (c and f). E-cadherin staining was patchy (d). 
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Figure 2-5 (C). After 5 months incubation in kidney capsule, BPH-1 cells formed larger 
tumors and invaded the host kidney (g, h, i, j). Tumor cells surrounded and intermingled 
with kidney tubes (Figure 4B, g and h-arrows). There were no clear margins between 
kidney and grafts. H & E staining of BPH-1 + NPF grafts revealed small grafts with 
minimal epithelial growth consistent with previous observations (k, arrow and l). Scale bar 
equals 50 µm.  
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Figure 2-6. The BPH-1
NPF-cyclinD1
 cells which were isolated from BPH-1 + NPF
cyclin D1
 
grafts exhibited a transformed phenotype. (A) Gross morphology of 3 months grafts of 
BPH-1
NPF
 (left) and BPH-1
NPF-cyclinD1
 (right). The volume of the BPH-1
NPF-cyclinD1
 grafts 
was significantly larger than the control grafts (Student’s t-test, P<0.01).  
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Figure 2-6 (B). In grafts of BPH-1
NPF
 cells, occasionally, epithelial cords were seen. (a) and 
their origin confirmed by SV-40 staining (b). No evidence of malignant growth or invasion 
was seen in these grafts. Scale bar equals 50 µm.  
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Figure 2-6 (C). BPH-1
NPF-cyclin D1
 tumors were larger than controls with areas of 
keratinization. (a). The grafts formed a pushing margin directly touching the host kidney 
(a, arrow). Small nests of epithelial cells with irregular shapes intermingled with stroma 
(d and e). Some infiltrative areas (b-arrow) were found to be composed of bubbly 
cytoplasm and indistinct cells borders (c-arrow). Minimally invasive growth into the 
kidney was seen in a few areas. The invading cells expressed SV-40T antigen (f, arrow). 
Scale bar equals 50 µm. k = host kidney. 
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Figure 2-6 (D). FACS analysis demonstrated striking differences in cell population 
distribution between BPH-1
NPF
 and BPH-1
NPF-cyclin D1
 cells. The majority (64%) of the 
BPH-1
NPF
 cells were in the G1/G0 phase of cell cycle. In contrast, in BPH-1
NPF-cyclin D1
 cells 
an abnormal peak which contains 55% of the total cell population is located close to but 
somewhat below where the G2/M peak would be expected. Additionally, polyploid cells 
composed of 23.1% of the total population in the BPH-1
NPF-cyclin D1
 cells. 
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Figure 2-7 (A). cDNA Microarray analysis identified similar gene expression profiles of 
the cyclin D1 overexpressing normal fibroblasts and CAFs compared with NPFs. Heat map 
colors reflect fold ratio values between each sample and NPF reference (see scale.) Results 
of a one-sample t-test comparing NPF
cyclin D1
 cells and CAFs vs. normal fibroblasts. Shown 
are the 118 unique genes up-regulated in both NPF
cyclin D1
 cells and CAFs compared to 
normal fibroblasts (q-value ≤ 0.1%.).  
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Figure 2-7 (B). Shown are the 51 unique genes down-regulated in both NPF
cyclin D1
 cells and 
CAFs compared to normal fibroblasts (q-value ≤ 0.1%.). 
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Figure 2-7 (C). Results of a two-sample t-test comparing NPF
cyclin D1
 cells with CAFs. 
Shown are the six unique genes upregulated in CAFs and 20 unique genes down-regulated 
in CAFs compared to cyclin D1 overexpressing cells (q-value ≤ 10%.) 
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Discussion 
The concept of stroma as a contributor to, and potentially as an initiator of, carcinogenesis 
have led to altered perceptions of the development and progression of epithelial 
malignancies. Histopathologic examination has shown clear differences in gene 
expression patterns between the reactive stroma of tumors and normal stroma, 
additionally these differences have clinical prognostic value (Ayala et al., 2003; Bosman 
et al., 1993; Tuxhorn et al., 2002). The importance of stromal-epithelial interactions in 
tumorigenesis has been demonstrated in many malignancies, including, carcinoma of the 
skin, colon, breast and prostate (De Cosse et al., 1973; Fukamachi et al., 1986; Singer et 
al., 1995; Wright et al., 1994). Stromal-epithelial interactions not only play an important 
role in normal development and adult growth quiescence of the prostate (Cunha et al., 
2004) but changes in these interactions can promote a malignant progression of initiated 
epithelium and result in tumorigenesis (Grossfeld et al., 1998; Hayward et al., 1997; 
Mueller and Fusenig, 2004). 
 
There are cases in which addition of a single dominant-acting oncogene is sufficient to 
transform a non-tumorigenic cell. For example, massive overexpression of c-myc 
converted normal prostatic epithelial cells to rapidly become an invasive prostate 
carcinoma cell (Williams et al., 2005), while lower levels of c-myc expression had similar 
but slower effects (Ellwood-Yen et al., 2003). Similarly loss of genes with tumor 
suppressor function can also contribute to malignancy (Wang et al., 2003). These 
observations emphasize the importance of genetic changes as key factors in malignancy. 
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Alterations in the microenvironment adjacent to the epithelial cells can drive 
non-tumorigenic cells to become malignant both in vivo and in vitro (Hayward et al., 
2001; Maffini et al., 2004; Pierce, 1974). Stromal factors can also elicit reversion of a 
malignant teratocarcinoma to a benign phenotype despite of genetic changes within the 
epithelial cells (Hayashi and Cunha, 1991; Mintz, 1978). The growth and differentiation 
of epithelial cells from R3327 Dunning prostatic adenocarcinoma (DT) were modified 
when reassociated with normal stromal environment. The epithelial cells were induced to 
differentiate to tall columnar secretory epithelial cells and tumorigenesis was remarkably 
diminished (Hayashi and Cunha, 1991; Hayashi et al., 1990). Experiments in mice 
suggested that genetic inactivation of the stromal TGF-RII receptor resulted in the 
transformation of normal epithelial cells (Bhowmick et al., 2004b). Bissell’s group 
demonstrated that by manipulating ECM proteins, human breast cancer cells reverted to 
normal functional cells in culture and tumorigenicity was reduced dramatically in mice 
(Weaver et al., 1997).  
 
Cyclin D1 is an important oncogene in many human cancers, but its function in prostate 
cancer is not clear (Bubendorf et al., 1999; Gumbiner et al., 1999; Kallakury et al., 1997). 
We show here that cyclin D1 is upregulated in prostate cancer cell lines indicating that it 
might be associated with prostate tumorigenicity. Overexpression of cyclin D1 can 
increase tumorigenicity of LNCaP cell lines (Chen et al., 1998). We have observed that 
BPH-1 cells in which cyclin D1 was overexpressed did not become tumorigenic under the 
influence of inductive rUGM in the tissue recombination model when grafted to SCID 
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mice. However, the cyclin D1 overexpressing cells did have a higher proliferation rate in 
vitro and in vivo and motility in vitro. Such observations indicated that this single gene is 
not enough to transform BPH-1 cells even in the face of SV40 large T antigen, which is 
expressed in these cells. This underlines the important point that increased proliferation 
per se is insufficient for malignant transformation. 
 
In marked contrast to the effects in epithelial cells, overexpression of cyclin D1 in primary 
cultures of benign human prostatic fibroblasts extended the lifespan and altered the 
behavior of the stromal cells, nonetheless falling short of directly inducing malignant 
transformation. Cyclin D1 induced these cells to behave in a manner similar to CAFs, 
imparting an ability to elicit malignant transformation in BPH-1 epithelial cells in a tissue 
recombination model. The cyclin D1 overexpressing fibroblasts have increased life span 
compared with NPFs. NPFs were all dead within 12 passages. However, the NPF
cyclin D1
 
cells appeared healthy after an additional 11 passages. NPFs overexpressing cyclin D1 may 
be selectively advantageous for the proliferation and survival characteristics often 
associated with oncogenesis compared with non-infected cells in the same mixture. 
However it should be noted that, as when expressed in epithelial cells, expression of cyclin 
D1 did not result in transformation of the stromal cell population. As a result of in vitro 
adaptation, cells may pick up generic alterations such as the mRNA changes we have seen 
in microarray data. However, NPF
cyclin D1
 cells are not fully immortal and are not 
tumorigenic by themselves. This is consistent with observations that CAFs are also not 
immortal and not tumorigenic per se, but have the ability to transform adjacent BPH-1 
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cells.  
 
By expressing cyclin D1 in stromal cells we demonstrated that benign stromal cell 
behavior can be modified to mimic that of cancer stromal cells. NPF
cyclin D1
 cells have a 
potential to transform BPH-1 cells similar to that seen with CAFs although with a reduced 
intensity. Tissue architecture in recombinants showed irregular epithelial cords and 
epithelium infiltrating into the stroma. This observation indicated that the presence of 
altered stromal cells in proximity to an initiated epithelium has an important biological 
impact on prostatic carcinogenesis. Expression of this single oncogene in the stroma may 
mimic the effects of CAFs on epithelium by modifying the local microenvironment. 
Specifically altering the expression of growth factors and ECM proteinases results in 
expansion and malignant progression of the initiated epithelial cells.  
 
BPH-1 cells form tumors after recombination with CAFs, and epithelial cells derived 
from these tumors (BPH1
CAFTD
) are tumorigenic without the stimulation of stromal cells 
when re-grafted to mice (Hayward et al., 2001). The present study shows that the 
tumorigenic behavior of BPH-1
NPF-cyclin D1
 cells (derived from recombination of BPH-1 + 
NPF
cyclin D1
 cells) also resulted in a permanent malignant transformation of epithelial cells 
similar to that seen with CAF.  
 
Cell cycle analyses of cells from malignant tissues have demonstrated the presence of 
aneuploid cells as well as normal diploid cells (Givan, 2001). In the present study, an 
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abnormal peak in cell cycle histogram of BPH-1
NPF-cyclin D1
 likely represented 
hyperdiploid cells. Many of these cells had multiple nuclei. It has been shown that 
aneuploidy is the possible underlying mechanism and potential consequences in the 
pathogenesis of human lung cancer (Masuda and Takahashi, 2002). Clinical progression 
of prostate cancer is also associated with formation of DNA aneuploidy (Koivisto, 1997). 
These data suggested that BPH-1
NPF-cyclin D1
 cells might be transformed through 
chromosomal changes (aneuploidy).  
 
The histological appearance BPH-1
NPF-cyclin D1
 tumors was consistent with poorly 
differentiated carcinoma. It is important to note that CAFs have elevated expression 
levels of cyclin D1 protein, and therefore many of their characteristics could be linked to 
the downstream consequences of this change. Microarray comparison of the NPF
cyclin D1
 
and CAFs vs. NPF showed highly concordant gene expression profiles. The same 118 
unique genes were up-regulated and 51 unique genes were down-regulated in NPF
cyclin D1
 
cells and CAFs when compared with NPFs. Relatively few significant differences in 
transcript abundance measurements between NPF
cyclin D1
 cells and CAFs were identified. 
These data indicate that cyclin D1 expression in stroma can critically affect paracrine 
interactions with adjacent epithelial cells in a manner resembling CAFs.  
 
In summary, the present study in this chapter demonstrated for the first time the 
importance of cyclin D1 as a potential regulator of paracrine interactions in prostate 
cancer progression. The cyclin D1 overexpressing fibroblasts have an increased life span 
 86 
and share many commonalities with CAFs making them a potentially useful research tool. 
Traditional therapy for all epithelial malignancies, including prostate cancer, has been 
targeted at the epithelial cells which progressively acquire genetic changes. The stroma 
may provide a more stable target at which to direct treatment, since the gene expression 
profile differs from that seen in normal tissues. We should also bear in mind that the 
tumor stromal compartment is heterogeneous and that CAFs are a mixed population of 
fibroblastic cells. Juxtacrine signaling between fibroblastic cells of different types may 
contribute to changes in overall paracrine signaling which boosts the growth of epithelial 
cells. Interactions with other stromal cell types including inflammatory cells or nerve 
cells also turn out to be of critical importance. A better understanding of these complex 
interactions within the stroma and between stroma and epithelium, and the manner in 
which these are influenced by gene expression in stromal cells will allow for the rational 
design of therapies aimed at inhibiting prostate tumor growth. 
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CHAPTER III 
 
CATHEPSIN D ACTS AS AN ESSENTIAL MEDIATOR TO PROMOTE 
MALIGNANCY OF BENIGN PROSTATIC EPITHELIUM. 
Introduction 
Cathepsin D is a ubiquitous lysosomal aspartyl endoproteinase which is overexpressed and 
hypersecreted by human breast cancer cells (Rochefort, 1992). Overexpression of 
cathepsin D has been shown to increase the risk of breast cancer metastasis. (Ferrandina et 
al., 1997; Foekens et al., 1999; Rochefort, 1992). Cathepsin D was shown to stimulate 
cancer cell proliferation (Westley and May, 1999). Cathepsin D may be responsible for 
positive regulation of proliferation, motility, and/or invasion of cells by triggering 
activation of ras/MAPK/ERKs (Laurent-Matha et al., 2005). Immunohistochemical studies 
indicated that cathepsin D not only promoted cancer cell proliferation by an autocrine 
mechanism, but also tumor angiogenesis via a paracrine mechanism by staining with 
PCNA, whose expression is associated with proliferating cells in late G1 and S phase 
(Berchem et al., 2002). It is the first time that the potential paracrine action of cathepsin D 
was found in the context of a tumor.  
 
Cathepsin D overexpression was shown to be important in epithelial growth, but also 
affects fibroblast behavior. Cathepsin D was required for fibroblast invasive growth using 
a three-dimensional (3D) coculture assay with breast cancer cells. Cathepsin D was found 
to be crucial for fibroblast invasive outgrowth and could act as a key paracrine 
communicator between breast cancer and stromal cells, independently of its catalytic 
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activity (Laurent-Matha et al., 2005). The mechanism of how cathepsin D involves in the 
paracrine signaling is still under investigation.  
 
There are a few studies which examined the function of cathepsin D in prostate cancer 
progression. Some data demonstrated that a greater expression of mature cathepsin D with 
a higher catalytic activity in prostate cancer specimens is the most notable difference from 
normal specimens (Cherry et al., 1998). The normal glands were, in general, found to be 
negative for cathepsin D expression, but carcinoma samples have greater positive punctate 
lysosomal staining. Therefore, cathepsin D may prove to be a useful marker of prostate 
cancer progression (Makar et al., 1994). Endogenous cathepsin D can possibly modulate 
androgen receptor function in LNCaP cells and in prostate cancer specimens. Its activity 
appears to differ significantly between normal and malignant tissue. Cathepsin D may play 
a pivotal role as a growth modulator in androgen-dependent prostate cancer (Mordente et 
al., 1998). Some studies also indicated that cathepsin D, which is produced by reactive 
stromal cells but not the cancer cells, influence the prognosis of breast cancer (Tetu et al., 
1999).  
 
As the carcinoma evolves, phenotypic changes and alterations in gene expression in the 
adjacent stroma may enhance the invasive potential of the epithelial tumor (Cunha et al., 
2002; Cunha et al., 2003). The microenvironment affects tumor formation, growth, 
invasiveness and metastasis. Stromal-epithelial interactions are mediated, in large part, by 
paracrine signaling between epithelial tumor cells and neighboring stromal fibroblasts (Ao 
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et al., 2007). In addition to receiving signals from epithelial cells, the stromal fibroblasts 
can also stimulate tumorigenesis by releasing factors which act on epithelial cells or 
exchange enzymes, growth factors and cytokines with epithelium to modify local 
extracellular matrix (ECM), stimulate migration and invasion, and promote proliferation 
and survival of tumor cells (Liotta and Kohn, 2001).  
 
In tissue recombination model, it was shown that human prostatic CAFs are capable of 
stimulating carcinogenesis and inducing the progression of an initiated epithelium (BPH-1 
cell line), while normal prostatic fibroblasts were incapable of stimulating such 
tumorigenesis (Olumi et al., 1999). The mechanistic basis by which stromal-epithelial 
interactions enhance the process of prostatic carcinogenesis and tumor invasion is 
beginning to be dissected and studied. TGF- pathway is a crucial component in this 
interaction (Ao et al., 2007; Ao et al., 2006). Cyclin D1 was also shown to be a mediator of 
carcinogenesis. Our previous study in chapter II demonstrated that cyclin D1 
overexpressing prostate fibroblasts (NPF
cyclin D1
) transformed BPH-1 cells and drove 
BPH-1 cells to be invasive in a similar manner to CAFs. Cathepsin D expression was 
increased 7 fold in NPF
cyclin D1
 cells and also in CAFs, indicating a possible role of 
cathepsin D as a paracrine mediator of cancer progression. 
 
In the chapter, we highlight the possibility that cathepsin D may participate in paracrine 
signaling interactions between epithelial cancer cells and NPF
cyclin D1
 cells or CAF cells. 
The expression of cathepsin D was examined in clinical samples and tissue recombinants. 
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The function of cathepsin D in NPF
cyclin D1
 cells was examined in a 3D coculture assay. We 
then went on to study the effects of knocking down cathepsin D in CAFs to investigate the 
importance of cathepsin D in this paracrine signaling interaction.  
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Methods 
Cells 
BPH-1 (a non-tumorigenic human prostatic epithelial cell), NPF and CAF cells were from 
our own stocks (Hayward et al., 2001). BPHfib and CAF cells were isolated from human 
prostate samples. NPF
cyclin D1
 cells was generated as discribed in chapter II (He et al., 
2007). Cells were maintained in RPMI 1640 (Gibco, Carlsbad, CA) with 1% 
antibiotic/antimycotic (Life Technologies, Grand Island, NY) and 5% Cosmic Calf Serum 
(CCS-HyClone, Logan, Utah).  
 
Generating genetically modified cell lines 
The pSuper.Retro-control (PSR- OligoEngine, Seattle, WA) and pSuper.Retro-cyclin D1 
shRNA (PSR-cyclinD1sh-kindly provided by Dr. Rene Bernards and Dr. Daniel Peeper 
from the Netherlands Cancer Institute) were transduced into CAFs by retroviral infection 
as described previously (Williams et al., 2005). The successfully infected cells were 
selected using puromycin (5ug/ml) to generate two cell lines (CAF
PSR
 and CAF
PSR-cyclin 
D1sh
). The pSilencer 2.1-cathepsin D1 shRNA vector was kindly provided by Dr. Daniel 
E. Johnson from the University of Pittsburgh Cancer Institute. We cut both pSilencer 
2.1-cathepsin D1shRNA and pSuper.Retro plasmids with HindIII and BamH1, and 
inserted the cathepsin D shRNA sequence to pSuper.Retro vector to generate the 
retroviral cathepsin D knockdown vector which is designated as PSR-cathepsinDsh. The 
PSR and PSR-cathepsinDsh were transduced into CAFs by retroviral infection as 
described previously (Williams et al., 2005). The successfully infected cells were selected 
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using puromycin (5g/ml) to generate two cell lines (CAFPSR and CAFPSR-cathepsinDsh). PSR 
and PSR-cathepsinDsh vector was retrovirally infected to NPF
cyclin D1
 cells to generate 
NPF
cyclin D1- control 
and NPF
cyclin D1-cathepsin Dsh 
respectively.  
 
Western blotting analysis 
Cells were grown in T75 cell culture flasks at 37

C until they were confluent. After 
washing with PBS three times, 300 µl cold lysis buffer (10 mM HEPES pH 7.9; 10mM 
KCl: 0.1mM EDTA; 0.1mM EGTA; 0.1mM DTT; 1 protease complete tablet (Roche, 
Indianapolis, IN)) were added to each flask. The cells were cooled on ice for 30 minutes 
with lysis buffer, and then were scraped from flasks. Cell lysates were sonicated 5 times (10 
second/time) and centrifuged for 20 minutes at 4°C. Protein concentrations were measured 
for western blotting. Twenty µg protein was loaded and electrophoresed through 10% 
NuPAGE BisTris gel (Invitrogen, Carlsbad, CA) and electrophoretically transferred to 
nitrocellulose membranes. Membranes were blocked with PBS-Tween20 with 5% non fat 
milk and incubated with mouse primary antibody to PTEN (1:1000, Santa Cruz 
Biotechnology, Santa Cruz, CA), Cdk2 (1:1000, Santa Cruz), Cdk4 (1:1000, Santa Cruz), 
Cdk6 (1:1000, Santa Cruz), cyclin E (1:1000, Santa Cruz), cyclin D1 (1:1000, BD 
Biosciences Pharmingen, San Jose, CA) ,-actin (1:5000, Sigma) or cathepsin D 
(1:1000, Cell Signaling, Denvers, MA) overnight and washed with PBS-Tween 20 for 1 
hour, and incubated with horseradish-Peroxidase linked anti-mouse secondary antibody 
(Amersham Biosciences, Piscataway, NJ, 1:1,000 dilution) for 1 hour. Bound antibodies 
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were visualized using enhanced chemiluminescence western blotting detection reagents 
(Amersham Bioscences).  
 
Tissue recombination and xenografting 
BPH + CAF
PSR
, BPH-1+ CAF
PSR-cyclinD1sh
, BPH-1 + CAF
PSR-cathepsin Dsh 
tissue 
recombinants were made as described in chapter II (Williams et al., 2005). 100k epithelial 
cells and 600k stromal cells were recombined to make the resultant recombinants. All the 
experiments were repeated 6 times.  Mice were sacrificed after 6 weeks and grafts were 
harvested, fixed, and paraffin embedded.  
 
Wound healing assays 
Confluent monolayers of NPF, NPF
cyclin D1
, NPF
cyclin D1-cathepsinD control 
and NPF
cathepsin Dsh
 
cells were grown in 6 well plates. Wound healing assays were performed as described in 
chapter II. Wounds were imaged at 0, 3, 6, and 8 hours post wounding and the cell 
migration rate into the wound was calculated. Experiments were performed in triplicate. 
 
Outgrowth assay 
100k NPF, NPF
cyclin D1
, NPF
cyclin D1-cathepsinD control
 or NPF
cyclin D1-cathepsin Dsh
 were 
resuspended at 4°C in Matrigel (0.2 ml, 10 mg/ml; Becton and Dickinson), and quickly 
added to a preset layer of Matrigel in 24-well plates as described previously (Garcia et al., 
1990). The top Matrigel layer was solidified at 37°C for 30 minutes and covered with 
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culture medium containing 10% FCS (0.5 ml). Cells outgrowth from the Matrigel was 
monitored under microscope after 14 days. 
 
Conditioned Medium 
NPF, NPF
cyclin D1
, NPF
cyclin D1- control
 or NPF
cyclin D1-cathepsin Dsh
 cells were seeded with 5% 
FCS in RPMI 1640 at a density of 500k per 75-cm
2
 flask, allowed to grow, and attached 
overnight. Confluent cultures of cells were rinsed twice in PBS and incubated for 3 days 
in RPMI + 0.5% FCS. The medium was collected, centrifuged, passed through a 0.45-µm 
filter (Millipore), and stored at –80°C for later use. Conditioned medium was thawed and 
diluted 1:1 with fresh DMEM + 0.5% FCS before use. BPH-1 cells were seeded at 20k 
per well in six-well plates in conditioned medium. The cultures were incubated for 3 days 
and the total number of BPH-1 cells was determined by direct counting in a 
hemacytometer. 
 
Immunofluorescence staining 
Cells were plated on glass (Superfrost) slides and allowed to attach and grow overnight. 
After fixation in methanol for 5 minutes at –20°C, samples were washed twice in PBS, 
blocked for 30 minutes with 5% goat serum (Vector Laboratories, Burlingame, CA), and 
incubated at room temperature for 1 hour with primary antibodies against-actin 
(1:500, Sigma), -actin (1:500, Sigma), vimentin (1:100; Sigma,) and wide spectrum 
keratin (1:100; DAKO, Carpinteria, CA) followed by washing for 30 minutes in PBS. 
Staining was visualized using fluorescence-conjugated secondary anti-rabbit IgG (whole 
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molecule) TRITC Conjugate (Sigma) or anti-mouse IgG (whole molecule) FITC 
Conjugate (Sigma). Slides were visualized and imaged using a Zeiss upright microscope 
with an attached Axiocam camera and proprietary software.  
 
Immunohistochemical staining 
Immunohistochemical staining was performed as previously described in chapter II. 
Tissue slides were then incubated with the primary antibody against cathepsin D (1:1000, 
Cell Signaling), Vimentin (1:500, Sigma) overnight. The polyclonal rabbit or mouse 
immunoglobulins/biotinylated anti-mouse secondary antibody (DAKO, Carpentiria, CA) 
was incubated for 60 minutes after the slides were washed with PBS buffer for 1 hour. 
After washing the slides in PBS extensively, slides were incubated in ABC-HRP complex 
(Vector Laboratories) for 30 minutes. Bound antibodies were then visualized by 
incubation with 3,3’ diaminobenzidine tetrahydrochloride (liquid DAB, DAKO). Slides 
were then rinsed extensively in tap water, counterstained with hematoxylin, and mounted.  
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Results 
Characterization of cyclin D1 overexpressing fibroblast cells 
Expression of epithelial and stromal markers was examined by immunofluorescence in 
cultured fibroblasts to monitor the phenotypic characteristics. Three markers of stromal 
differentiation (-actin, -actin and vimentin) were examined in NPF, NPFcyclinD1, BPHfib 
and CAF cells. Keratin staining (wide spectrum) was be used to confirm lack of epithelial 
contamination. It was found that all the cells maintain fibroblastic or myofibroblastic 
characteristics with high expression of vimentin, and moderate expression of -actin and 
- actin (Figure 3-1). Keratin expression was negative in all four cell lines which 
indicated that they are all fibroblasts without epithelial cell contamination. 
 
Cathepsin D increased the motile ability of NPF
cyclin D1
cells 
Chapter II showed that NPF
cyclin D1
 cells can elicit permanent malignant transformation in 
initiated but non-tumorigenic BPH-1 cells, similar to the malignant changes which have 
been described in BPH-1 + CAF tissue recombinants. In order to investigate the underlying 
mechanism of this malignant transformation, we at first compared the effect of cyclin D1 
overexpression on the migration of NPFs. It was shown that NPF
cyclin D1
 cells were found to 
have enhanced motile ability in wound healing assay compared with control NPFs (Figure 
3-2, A). This difference was clear after 3 hours and was very marked after 8 hours 
(Student’s t-test, P<0.01). However, when cathepsin D was knocked down by retroviral 
infection in NPF
cyclin D1
 cells, the motile ability was reduced in NPF
cyclin D1-cathepsin Dsh
 cells. 
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The observation suggested that cathepsin D may be an essential mediator of NPF
cyclin D1 
migration in vitro.  
 
Cathepsin D is important for 3D outgrowth of NPF
cyclin D1 
fibroblasts 
We next studied if cathepsin D is important for NPF
cyclin D1
 fibroblast outgrowth in 3D 
matrices. As shown in Figure 3B, overexpression of cyclin D1 promoted outgrowth of 
normal prostatic fibroblasts embedded into Matrigel. After 14 days of culture, NPF
cyclin D1
 
cells had adopted a stellate morphology of growing and invasive colonies with 
protrusions sprouting into the surrounding matrix (Figure 3-2, B). In contrast, normal 
prostatic fibroblasts presented a well-delineated spherical appearance of quiescent cells 
and grew poorly, neither invading nor forming protrusions to the surrounding matrix 
(Figure 3-2, B). We then went on to examine if cathepsin D is important for NPF
cyclin D1
 
outgrowth from matrigel. Cathepsin D was knocked down in NPF
cyclin D1
 cells by 
retroviral infection. It was found that the invasive outgrowth of NPF
cyclin D1
 was reversed 
by knocking down cathepsin D those cells (Figure 3-2, B). Neither invasion nor 
protrusion formation into the surrounding matrix was found in NPF
cyclin D1-cathepsin Dsh
 cells. 
But the NPF
cyclin D1-control
 cells maintained the invasive growth feature. These data 
indicated that cathepsin D is an essential factor of promoting NPF
cyclin D1 
cells invasion in 
vitro. Inhibition of cathepsin D leads to a decreased in fibroblast invasive growth. These 
data indicated that cathepsin D might also be an potential paracrine factor in  
stromal-epithelial interaction in vivo.  
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Evaluation of cathepsin D as a paracrine mediator of neoplastic epithelial cell growth 
in vitro 
The identification of cyclin D1 induced expression of transcripts encoding cathepsin D 
with the potential to influence epithelial proliferation in vitro prompted experiments 
designed to determine whether conditional medium from NPF
cyclin D1
 fibroblasts could 
stimulate the growth of immortalized prostate epithelial cells (BPH-1). To determine 
whether the influence of NPF
cyclin D1
  on epithelial growth resulted from secretary factors. 
We generated conditioned medium from NPF and NPF
cyclin D1
 cells, and measured BPH-1 
cell numbers after growth for 3 days in the different conditioned media. The proliferation of 
BPH-1 cells was stimulated 1.7-fold (P<0.01) with medium from NPF
cyclin D1
, when 
compared with medium from with NPF (Figure 3-2, C). Cathepsin D expression in 
NPF
cyclin D1
 conditional medium was also upregulated compared with NPF
 
conditional 
medium (Figure 3-2, D). These results suggest that a significant component of NPF
cyclin D1
 
proliferative influence toward epithelium is mediated through secreted cathepsin D.  
 
Evaluation of cathepsin D as a paracrine mediator of neoplastic epithelial cell growth 
in tissue recombinants in vivo 
To examine whether CAF or NPF
cyclin D1
 induces cathepsin D expression in vivo and also to 
examine if cathepsin D expression in tissue recombinants correlates what we have seen in 
clinical samples, we checked cathepsin D expression in BPH-1 + NPF, BPH-1 + NPF
cyclin 
D1
, BPH-1 + rUGM and BPH-1+CAF tissue recombinants. Among these recombinants, 
CAF and NPF
cyclin D1 
can drive non-tumorigenic BPH-1 cells to undergo malignant 
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transformation (Hayward et al., 2001; He et al., 2007). BPH-1 + NPF, and BPH-1 + UGM 
formed benign structures and none of the epithelial cells were transformed. 
Immunohistochemical staining revealed minimal expression of cathepsin D in BPH-1 + 
NPF and BPH-1 + UGM recombinants. In marked contrast, cathepsin D expression in was 
elevated in BPH-1 + NPF
cyclin D1
 and BPH-1 + CAF recombinants (Figure 3-3, A). This 
observations are consistent with what we have seen in clinical samples. This result 
indicated that upregulation of cathepsin D might be involved in the interaction that between 
NPF
cyclin D1 
or CAFs and non-tumorigenic BPH-1 cells. However, this correlation did not 
address the question whether the upregulation is an effect of tumorigenicity
 
or is a required 
paracrine signaling event for epithelial transformation in vivo.  
 
BPH-1
NPF-cyclin D1
 cells had increased cathepsin D and CDK2, but not CDK4/6 
expression 
In order to understand the mechanism by which stromal cyclin D1 or CAFs affects the 
prostate cancer cellular processes through paracrine signaling, western blotting assays were 
performed on BPH-1
NPF
, BPH-1
CAFTD1
 and BPH-1
NPF-cyclin D1
 cells (the epithelial cells 
isolated from BPH-1 + NPF
cyclin D1
 tumors) to examine expression levels of several genes 
which are involved in cell cycle regulation. Our results showed that overexpression of 
cyclin D1 in the stroma increased CDK2 and cyclin E protein expression in the adjacent 
epithelium (Figure 3-3, B). No change was seen in CDK4 and CDK6 protein levels. These 
data indicated that the tumorigenic response of BPH-1 to either CAFs or NPF
cyclin D1
 cells 
resulted in an increased expression of cyclinE/cdk2, but not cyclin D1/cdk4/cdk6 in the 
 100 
permanent transformed epithelium. These  data were consistent with our previous finding 
that cyclin D1 upregulation in epithelium might not be essential for tumorigenicity (He et 
al., 2007). Cathepsin D protein expression level was upregulated in BPH-1
CAFTD1
 and 
BPH-1
NPF-cyclin D1
 cells compared with control BPH-1
NPF 
cells. This observation suggested 
that NPF
cyclin D1 
secreted cathepsin D which could affect adjacent BPH-1 cells. The stromal 
fibroblasts stimulated epithelial tumorigenesis by releasing cathepsin D which acts on 
epithelial cells to stimulate proliferation and invasion.  
 
Cyclin D1 and cathepsin D are both required for CAF induced tumorigenicity in vivo 
To examine the function of cyclin D1 and cathepsin D in CAF-induced tumorigenicity in 
BPH-1 transformation, we used retroviral transfection of shRNA vectors to knock down 
either cyclin D1 or cathepsin D expression in CAF cells. Western blotting indicated there 
were approximately 50% knockdown of cyclin D1 and 95% cathepsin D protein expression 
respectively (Figure 3-4, C). It was found that BPH-1 + CAF
cyclinD1sh
 and BPH-1 + 
CAF
cathepsin Dsh
 recombinants formed significantly smaller grafts compared with BPH-1+ 
CAF grafts (Figure 3-4, A). Histologically, BPH-1 + CAF recombinants formed 
adenosquamous carcinoma as previously described. Knockdown of either cyclin D1 or 
cathepsin D recombinants formed small, benign cords with no tumorigenic response 
(Figure 3-4, B). Similarly, after cathepsin D is knocked down in NPF
cyclin D1
 cells, their 
ability to transform BPH-1 cells was reduced (data not shown). Interestingly, cathepsin D 
expression in CAF
cyclinD1sh
 cells was downregulated and cyclin D1 expression in 
CAF
cathepsin D
 cells was also downregulated suggesting some form of co-regulation of these 
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proteins (Figure 3-4, C). 
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Figure 3-1. Characterization of cyclin D1 overexpressing fibroblasts. Three markers of 
stromal differentiation (-actin, -actin and vimentin) were examined in NPF, NPFcyclinD1, 
BPHfib and CAF cells. Keratin staining was be used to confirm lack of epithelial 
contamination. All the cells maintain fibroblastic characteristic with high expression of 
vimentin, and moderate expression of -actin and -actin. Keratin expression was 
negative in all four cell lines.  
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Figure 3-2. Cathepsin D is a critical mediator between BPH-1 cells and NPF
cyclin D1
 in vitro. 
(A) NPF
cyclin D1
 cells had enhanced motile ability in wound healing assay compared with 
control NPFs. The motile ability was reduced in NPF
cyclin D1-cathepsin Dsh
 cells. (B) Cathepsin 
D is important on 3D outgrowth of NPF
cyclin D1 
fibroblasts. Overexpression of cyclin D1 
promoted outgrowth of normal prostatic fibroblasts embedded into Matrigel after 14 days 
of culture. The invasive outgrowth of NPF
cyclin D1
 was reversed by knocking down 
cathepsin D those cells. (C) Evaluation of cathepsin D as a paracrine mediator of 
neoplastic epithelial cell growth in vitro. (D) Cathepsin D expression in NPF
cyclin D1
 
conditional medium was also upregulated compared with NPF
 
conditional medium  
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Figure 3-3. Evaluation of cathepsin D as a paracrine mediator of neoplastic epithelial cell 
growth in tissue recombinants in vivo. (A) Immunohistochemical staining revealed 
minimal expression of cathepsin D in BPH-1 + NPF and BPH-1 + UGM recombinants. In 
marked contrast, cathepsin D expression in  BPH-1 + NPF
cyclin D1
, BPH-1 + CAF were 
induced. (B) BPH-1
NPF-cyclin D1
 cells had increased cathepsin D and CDK2/cyclin E, but not 
cyclin D1 expression. Overexpression of cyclin D1 in stromal environment could increase 
CDK2 and cyclin E protein expression in the adjacent epithelium. But there was no change 
in CDK4 and CDK6 protein levels. Cathepsin D protein expression level was upregulated 
in BPH-1
NPF-cyclin D1
 and BPH-1
CAFTD1
 compared with control BPH-1
NPF 
cells. 
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Figure 3-4. Cyclin D1 and cathepsin D are required for CAF induced tumorigenicity in 
vivo. (A) BPH-1 + CAF
cyclinD1sh
 and BPH-1 + CAF
cathepsin Dsh
 recombinants formed 
significantly smaller grafts compared with BPH-1+ CAF grafts. (B) Histologically, BPH-1 
+ CAF recombinants formed adenosquamous carcinoma. Knockdown recombinants 
formed benign, small cords structure with no tumorigenic response. (C) Western blotting 
indicated there were 50% knockdown of cyclin D1 and 95% cathepsin D protein expression 
CAF
cyclinD1sh
 and CAF
cyclinD1sh
 cells respectively. Cathepsin D expression in CAF
cyclinD1sh
 
cells was downregulated and cyclin D1 expression in CAF
cathepsin D
 cells was downregulated 
as well.  
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Figure 3-5. Cathepsin D plays a crucial role for prostatic fibroblast outgrowth and may 
favor prostate tumor progression via a paracrine loop. 
Epithelial-stromal interactions 
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Discussion 
A number of chemokines and cytokines have been shown to involve in stromal-epithelial 
interaction in prostate cancer progression. Recent report suggested that cross talk between 
paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human 
prostatic epithelium (Ao et al., 2007). The authors highlighted the links between 
TGF-CXCR12/SDF-1 pathways and showed that these pathways are linked paracrine 
factors contributing to in CAF-driven tumorigenesis in vivo.  
 
Tumor is a heterogenous disease, therefore many additional pathways are likely involved 
in stromal-epithelial interaction. Invasive prostate tumor stroma displayed induction of 
genes encoding ECM proteins and ECM degrading enzymes including members of the 
cathepsin family. Recent elegant study indicated that cathepsin D was robustly induced in 
stromal cells derived from prostate intraepithelial neoplasia (PIN) and invasive cancer in 
a multistage model of prostate carcinogenesis by cDNA microarray analysis of 
laser-microdissection (Bacac et al., 2006). The human ortholog of cathepsin D identified 
in the stromal reaction to tumor progression in this mouse model was observed to be 
expressed in several human cancers, including prostate cancer. Cathepsins have been 
suggested to participate in the progression of a variety of human cancers (Gocheva et al., 
2006; Joyce et al., 2004; Joyce and Hanahan, 2004; Nomura and Katunuma, 2005). 
Cathepsins have recently been shown to be upregulated in pancreatic tumor model and 
contribute to invasive tumor growth (Gocheva et al., 2006). Cathepsin D is overexpressed 
and hypersecreted by epithelial breast cancer cells and stimulates their proliferation 
(Laurent-Matha et al., 2005). Clinical studies indicated that cathepsin D overexpression is 
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associated with increased risk of breast cancer metastasis and patient survival rate 
(Foekens et al., 1999; Maurizi et al., 1996). Cathepsin D is also crucial for fibroblast 
invasive outgrowth and acts as a paracrine communicator between the epithelial and 
stromal tissues. Cathepsin D was proposed to be mitogenic and to assist cancer cells in 
digesting ECM during tumor invasion (Laurent-Matha et al., 2005).  
 
Our previous data have shown that overexpression of cyclin D1 in primary cultures of 
benign human prostatic fibroblasts extended the lifespan, altered the behavior of the 
stromal cells and induced malignant transformation of adjacent epithelium in vivo (chapter 
II) (He et al., 2007). Cyclin D1 induced these cells to behave in a manner similar to CAFs, 
towards the non-tumorigenic BPH-1 cells in a tissue recombination model. Stromal 
reactions to tumor growth are accepted to support tumor progression by providing growth 
factors, cytokines or chemokines that promote tumor cell survival, proliferation and 
migration (Ao et al., 2007; Olumi et al., 1999). The data presented here provide important 
messages by which paracrine signaling can promote tumorigenesis between tumor stroma 
and epithelium. 
 
In this chapter, we proposed that cathepsin D is a crucial mediator between BPH-1 and 
either NPF
cyclin D1 
or CAFs. Cathepsin D is upregulated in both NPF
cyclin D1 
cells and CAFs 
as determined by microarray and western blot analysis (He et al., 2007). NPF
cyclin D1 
cells 
have increased motile ability compared with control NPFs in a wound healing assay. By 
knocking down cathepsin D in NPF
cyclin D1 
cells, their motile ability was decreased. Also, 
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the invasive growth of NPF
cyclin D1
 cells was inhibited by knocking down cathepsin D in 
those cells. The stellate morphology of growing and invasive colonies with protrusions 
sprouting into the surrounding matrix of NPF
cyclin D1 
cells disappeared after cathepsin D 
expression was decreased. The cell went back to a quiescent growth status as seen in 
NPFs.  
 
Since cathepsin D is a secreted factor, we showed here that NPF
cyclin D1 
conditioned 
medium promoted the growth of BPH-1 cells. In order to determine that cathepsin D is 
the mediator of this growth promotion, we used the conditioned medium from the 
cathepsin D knock down NPF
cyclin D1
 cells to culture BPH-1 cells. It was found the growth 
promotion to BPH-1 cells was partially inhibited. Therefore, cathepsin D is necessary for 
NPF
cyclin D1
 cells to promote the epithelium growth in vitro.  
 
In a tissue recombination model, cyclin D1 and cathepsin D upregulation in NPF
cyclin D1
 
fibroblasts or CAFs favors BPH-1 growth in vivo by secreting and exchanging this 
protease to help BPH-1 cells digest ECM and invade to host kidney. As tumorigenesis 
progresses, the tumor cells  express elevated cathepsin D. We showed that during 
malignant transformation, the isolated BPH-1
NPF-cyclin D1 
cells from BPH-1 + NPF
cyclin D1
 
tumors continued to express upregulated cathepsin D. The data might suggest that the 
BPH-1
NPF-cyclin D1 
cells were tumorigenic alone when grafted to kidney capsule of SCID 
mice as a result of upregulated cathepsin D.  
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Our previous data showed that NPF
cyclin D1 
cells and CAFs elicited permanent malignant 
transformation of BPH-1 cells (Hayward et al., 2001; He et al., 2007). Both cyclin D1 and 
cathepsin D were shown to be upregulated in NPF
cyclin D1 
cells and CAFs. When cyclin D1 
or cathepsin D expression was knocked down in CAFs by retroviral transduction, CAFs 
had much reduced activity to transform BPH-1 cells. In the CAF
cyclin D1sh
 cells, cathepsin 
D was also downregulated. This confirmed our hypothesis that cathepsin D is an 
important mediator between BPH-1 and CAFs. Interestingly, in the CAF
cathepsin Dsh 
cells, 
cyclin D1 is also downregulated. This phenomenon makes sense because cyclin D1 is an 
cell cycle mediator, CAF
cathepsin Dsh
 cells had lost their ability to transform BPH-1 resulting 
in reduced proliferation and growth. The reduced proliferation and growth reciprocally 
promoted cells to secrete less cathepsin D. This loop effect between cyclin D1 and 
cathepsin D disfavored the interactions between stroma and epithelium. Similarly, when 
cathepsin D was knocked down in NPF
cyclin D1 
cells, these cells also had reduced ability to 
transform BPH-1 cells. These data indicated cathepsin D is not only in important 
mediator of stroma-epithelial cross talk in vitro, but also an essential component to favor 
this interaction in vivo.  
 
Our study demonstrated that cathepsin D plays a crucial role in prostatic fibroblast 
outgrowth and may favor prostate tumor progression acting via a paracrine loop. Under 
these circumstances, cathepsin D is overexpressed and secreted by fibroblasts, and is 
captured in vivo by epithelial cells. The resultant cathepsin D overexpression in tumor 
epithelium promotes proliferation and stimulates motility and invasion of epithelium and 
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consequently enhance tumor-host homeostasis (Figure 3-6). The identification of factors 
such as cathepsin D that participate in the tumor-stroma communication might be crucial 
for the development of new stromal therapy of prostate cancer based on the fact that 
stroma might be a more stable target compared with the moving epithelium.  
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CHAPTER IV 
 
FUNCTION OF PTEN IN NEW HUMAN IN VIVO MODELS REPRESENTING 
DISTINCT GRADES OF PROSTATE CANCER 
 
Introduction 
PTEN is one of the most frequently inactivated tumor suppressor genes in human tumors 
including prostate cancer. In humans, PTEN undergoes loss of heterozygosity (LOH) at 
relatively advanced stages in many cancers (Di Cristofano et al., 1998; Fujiwara et al., 2000; 
Garcia et al., 1999). The PTEN gene encodes a dual specificity phosphatase that regulates 
signal transduction pathways. PTEN mainly functions as a lipid phosphatase and targets 
phosphatidylinositol 3,4,5-trisphosphate (PIP-3) (Maehama and Dixon, 1998). By 
dephosphorylating PIP-3, PTEN can downregulate the Akt/PKB signaling pathway thus 
promoting cell survival and inhibiting apoptosis. PTEN can also antagonize the activity of 
PIP-3 affecting the G1 cell cycle transition (Wymann and Pirola, 1998). 
 
PTEN is located at 10q23, a commonly deleted region in prostate cancer (DeMarzo et al., 
2003; Visakorpi, 1999; Visakorpi, 2003). The biological importance of PTEN is evident from 
the early embryonic lethality of homozygous mutants. PTEN heterozygous mice develop 
cancers or dysplasias of multiple tissues including prostate (Di Cristofano et al., 2001; Di 
Cristofano et al., 1998; Suzuki et al., 1998). Loss of function of Nkx3.1 and PTEN cooperate 
in transgenic mouse models of prostate cancer progression (Abate-Shen et al., 2003). Since 
heterozygous and homozygous deletion of PTEN in animal models can result in prostate 
cancer, we were interested in identifying if and how PTEN suppression could play a role in 
initiation and progression of models of human prostate cancer and investigating responses to 
stromal environment.  
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Genetic insults to prostatic epithelium have been postulated to alter paracrine signaling to the 
prostatic smooth muscle (Hayward et al., 1997). Phenotypic changes consistent with this 
concept have been reported in stromal cells associated with human prostate tumors (Tuxhorn 
et al., 2002). Such changes have been demonstrated to be prognostic indicators of disease 
progression (Ayala et al., 2003). Presently, the profile of genetic changes in epithelium which 
results in a loss of normal stromal differentiation is not clearly understood. Stromal-epithelial 
interactions play a key role in the development and adult maintenance the prostate (Cunha 
and Young, 1992). Previous studies have shown that the inductive mesenchymal cells of 
normal prostate can suppress the growth of well differentiated prostate tumor cells (Hayashi 
et al., 1990). These results suggest that not all genetic lesions are sufficient to elicit 
significant alterations in the stromal-epithelial signaling axis with the additional possibility 
that fully differentiated prostate smooth muscle acts to restrain prostate tumor growth 
perhaps until a threshold of genetic damage has occurred. Such a mechanism suggests that 
stroma normally acts to suppress tumorigenesis and may explain the high incidence of small 
slow growing or latent prostate tumors which are found at autopsy in men who die from 
causes unconnected to prostate cancer (Franks, 1954b; Franks, 1976). In such a scenario 
these foci will not progress to an invasive phenotype until they accumulate a profile of 
genetic changes allowing them to escape the growth control exerted by the normal adjacent 
stroma. After the threshold is reached, the stromal microenvironment is altered in comparison 
to normal stroma and exhibits features of stroma involved in wound repair. The reactive 
stroma includes elevated numbers of myofibroblasts and fibroblasts with induced vimentin 
expression (Tuxhorn et al., 2002).  
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In this chapter, we examined the hypothesis that the ability of human prostatic epithelial cells 
to induce and maintain smooth muscle differentiation in adjacent stroma is negatively related 
to the level of genetic damage sustained by those epithelial cells. Suppression of PTEN was 
examined to determine the effects of stromal cells on the ability to transform epithelial cells 
and to affect differentiation of the local microenvironment.  
 115 
Methods 
Cells 
BPH-1 (a non-tumorigenic human prostatic epithelial cell), and its tumorigenic derivatives 
BPH
CAFTD1
 and BPH
CAFTD2
, PrE (prostatic epithelial cells)1 and PrE3 were from our own 
stocks (Hayward et al., 1995; Hayward et al., 2001). PrE cells were isolated from human 
benign prostate tissue and spontaneouly immortalized.PC3, DU145 and LNCaP were 
obtained from ATCC (Rockville, MD, USA). BPH-1
PSR
 (pSuper.Retro empty vector infected 
BPH-1 cells), BPH-1
PTENsh 
(pSuper.Retro PTEN shRNA vector infected BPH-1 cells), PrE1
PSR
 
(pSuper.Retro empty vector infected PrE1 cells), PrE1
PTENsh, 
(pSuper.Retro PTEN shRNA 
infected PrE1 cells), PrE3
PSR
 (pSuper.Retro empty vector infected PrE3 cells) PrE3
PTENsh 
(pSuper.Retro PTEN shRNA vector infected PrE2 infected cells), PrE3
pLNCX-control
 (pLNCX 
control vector infected PrE3 cells), PrE3
pLNCX-PTENsh
 (pLNCX PTEN shRNA vector infected 
PrE3 cells) and PrE3
pLNCX-myrAKT
 (pLNCX myristolated-Akt vector infected PrE3) cells were 
generated as described below. 957E/hTERT cells were generously supplied by Dr. John 
Issacs (Johns Hopkins). Cells were maintained in RPMI 1640 (Gibco, Carlsbad, CA) with 1% 
antibiotic/antimycotic (Life Technologies, Grand Island, NY) and 5% Cosmic Calf Serum 
(CCS-HyClone, Logan, Utah).  
 
Generating genetically modified cell lines 
pSuper.Retro vector (OligoEngine, Seattle, WA) was used as a backbone to clone a PTEN 
short hairpin RNA (shRNA) sequence. A 19 nucleotide PTEN target sequence 
(5’AGATGAGAGACGGCGGCGG3’) corresponding to nucleotides 206-224 of PTEN 
mRNA was selected for constructing PTEN shRNA vector (Ning, 2004 #8479). 
pSuper.Retro empty and pSuper.Retro-PTENsh constructs were transduced to targeted 
 116 
BPH-1 and PrE3 cells using retroviral infection as described in chapter II. Successfully 
infected cells were selected by 5µg/ml puromycin (Sigma) for 3 days. pLNCX control and 
pLNCX myr-Akt vectors were kindly provided by Dr. Hideyuki Miyauchi at Chuba 
University in Japan. PrE3 cells were gifts from Dr. Dean Tang at MD Anderson Cancer 
Center. PrE3
pLNCX control
 and PrE3
pLNCX-myr-Akt
 cells were generated by retroviral infection as 
described in chapter II and selected by 400µg/ml G418 for a week.  
 
Western blotting analysis 
Western blotting analysis was performed as previously described in chapter II. Membranes 
were incubated with mouse monoclonal antibody to PTEN (Santa Cruz Biotechnology, Santa 
Cruz, CA, 1:1,000 dilution), rabbit polyclonal phospho-Akt (Ser 473) (1:1000, Cell 
Signaling, Denvers, MA) and -actin (1:5000, Sigma) overnight and washed with 
PBS-Tween 20 for 1 hour, and incubated with horseradish-Peroxidase linked anti-mouse 
secondary antibody (Amersham Biosciences, Piscataway, NJ, 1:1,000 dilution) for 1 hour. 
Bound antibodies were visualized using enhanced chemiluminescence western blotting 
detection reagents (Amersham Bioscences). PTEN expression levels were normalized to 
-actin and quantitated using NIH Image J software  (http://rsb.info.nih.gov/ij/). 
 
Growth curves 
BPH-1
PSR
 and BPH-1
PTENsh
 cells were plated in a 24-well plate (1000 cells/well) in RPMI 
1640 medium supplemented with 5% CCS. After the cells had attached overnight, 300 µl 
Cell Titer 96 Aqueous One Solution (Promega, Madison, WI) was added at indicated times 
(1, 2, 3, 4, and 5 days) to each well and the absorbance was measured at 490 nm after 3 hours 
incubation. Experiments were performed in triplicate. 
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Wound healing assays 
Confluent monolayers of BPH-1
PSR
 and BPH-1
PTENsh
 cells were grown in 6 well plates. 
Wounds were imaged at 0, 3, 6, and 9 hours post wounding and the cell migration rate into 
the wound was calculated. Experiments were performed in triplicate. 
 
Transwell migration assay 
Detail method was described in chapter II. Results from at least three experiments were 
expressed as the mean relative cell migration ± SD, with that of BPH-1
PSR 
cells set at 1. 
 
Boyden chamber assay 
Detail method was described in chapter II.  
 
Tissue recombination and xenografting 
BPH-1
PSR
+ rUGM, BPH-1
PTENsh 
+ rUGM, PrE3
pLNCX-control 
+ rUGM and PrE3
pLNCX-myrAkt
 + 
rUGM tissue recombinants were made as previously described in chapter II (Hayward et al., 
1999). 100k BPH-1
PSR
 or BPH-1
PTENsh
, 600k PrE3 
pLNCX-control 
or PrE3
pLNCX-myrAk
 were 
recombined with 300k rUGM cells. All the experiments were repeated 6 times. Mice with 
BPH-1 grafts were sacrificed after 2 months and mice with PrE grafts were sacrificed after 6 
months and grafts were harvested, fixed, and paraffin embedded.  
 
Immunohistochemical and Immunofluorescence staining 
Immunohistochemical and immunofluorescence methods have been described previously in 
chapter II (Ao et al., 2006; Williams et al., 2005). Briefly, primary antibodies against -actin 
(1:1000, Sigma), -actin (1:1000, Sigma), vimentin (1:1000, sigma), AR (1:1000, Santa Cruz 
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Biotechnology,), E-cadherin (1:1000, BD Biosciences PharMingen, San Diego, CA), 
anti-phospho histone H3 (1:200, Upstate, Lake Placid, NY), CK14 (1:100, gift from E. B. 
Lane, University of Dundee), and Rabbit polyclonal to Ku 70 (1:500, Abcam, Inc., 
Cambrige, MA) were incubated with tissue sections at 4
°
C overnight. Polyclonal rabbit 
immunoglobulins/biotinylated anti-mouse or mouse immunoglobulins/biotinylated 
anti-rabbit secondary antibody (DAKO, Carpinteria, CA) were incubated for 60 minutes the 
next day after the slides were washed with PBS buffer for 1 hour for immunohistochemical 
staining of  -actin, -actin, vimentin, AR, E-cadherin and anti-phospho histone H3. The 
secondary anti-rabbit IgG (whole molecule) TRITC Conjugate (Sigma) or anti-mouse IgG 
(whole molecule) FITC Conjugate (Sigma) was used for immunofluorescence staining of Ku 
70, CK14 or vimentin for immunofluorescence.  
 
Cell Cycle Analysis 
Cell cycle analysis of BPH-1
PSR 
cells and BPH-1
PTENsh 
cells was performed using the method 
described in chapter II. 
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Results 
PTEN expression is downregulated in prostate cancer cell lines 
PTEN expression was examined by Western blotting in the prostate cancer cell lines, 
PC3, DU145, LNCaP, BPH
CAFTD1
 and BPH
CAFTD2
 and in a subset of non-tumorigenic 
PrE1, 957E/hTERT, PrE3 and BPH-1 prostatic cells. PTEN expression was found to be 
lower in all of the cancer cells as compared to the non-tumorigenic prostatic cells (Figure 
4-1, A). Non-tumorigenc epithelial cells had the highest PTEN expression, but malignant 
cell lines have a lower PTEN expression level. These data crudely correlate PTEN 
expression with tumorigenicity.  
 
Internal mutation and deletion of PTEN is detected in BPH
CAFTD
 cell lines but not in 
PH-1 cells 
To better understand the genomic instability of the BPH-1 derived human prostate cancer 
cell lines (BPH
CAFTD1
 and BPH
CAFTD2
), leading to decrease of PTEN expression, we 
designed primers  to amplify the PTEN genomic DNA sequence by RT-PCR. The PCR 
products were cloned into T-easy and sequenced to examine differences between cell lines. 
Sequence analysis indicated that the entire coding sequence was intact in the parental 
BPH-1 cells. In contrast, the BPH
CAFTD
 cell lines, contained point mutations, insertions and 
deletions in the  five prime untranslated region(5’UTR) of mRNA (messenger RNA) . As 
shown in Figure 4-1, B, two obvious insertions (9 bp and 15 bp) and one deletion (28 bp) 
were found in BPH
CAFTD1
 cells in the 5’UTR. Since no deletions, insertions, or mutations 
were found in the coding sequence of BPH
CAFTD
 cell lines, the downregulation of PTEN in 
 120 
these cells may be due to problems related to transcription initiation, incorrect translation 
start site, or mRNA instability. These data are consistent with findings that clinical tumors 
frequently have acquired mutations in noncoding regions of PTEN (Liaw et al., 1997; Liu 
et al., 1997). Our data correlate loss of PTEN with tumorigenicity but, like similar 
correlations seen in patient samples, do not address whether this correlation is a cause or an 
effect of malignant change. In order to address this question, we tested the consequences of 
knocking down PTEN in non-tumorigenic prostatic epithelial cells.  
 
Suppression of PTEN in BPH-1 cells can increase cell migration, and invasion in vitro 
Western blotting showed that BPH-1
PTENsh 
cells have a 0.55 fold decrease in PTEN 
expression compared with control BPH-1
PSR
 cells after normalization to -actin 
expression (Figure 4-2, A). Phospho-Akt expression was elevated in the PTEN 
knockdown cells (2.2 fold), confirming functional changes predicted by this 
manipulation. BPH-1
PTENsh
 cells showed enhanced mobility in wound healing, transwell 
migration, and Boyden chamber assays. Wound healing assays showed that BPH-1
PTENsh 
cells were significantly more motile than control BPH-1
PSR
 cells. This difference was clear 
after 6 hours (Student’s t-test, P<0.01) (Figure 4-2, B). In a transwell migration study, more 
BPH-1
PTENsh 
cells migrated through the uncoated Boyden chambers to the underside of the 
insert in a 12 hour response to conditional medium containing 1% CCS than BPH-1
PSR
 
cells (Student’s t-test, P<0.01) (Figure 4-2, C). These data confirmed the elevated motility 
of BPH-1
PTENsh
 cells. An invasion assay, in which the inside chamber was coated with 
matrigel to mimic the in vivo extracellular matrix, demonstrated that BPH-1
PTENsh
 cells had 
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significantly increased invasive activity in vitro (Student’s t-test, P=0.01) (Figure 4-2, D). 
Collectively these assays showed that when PTEN expression is suppressed, BPH-1 cells 
acquired an enhanced motility and invasive ability in vitro.  
 
BPH-1
PTENsh
 cells were deficient in cell cycle control and had a higher proliferation 
rate compared with control cells 
Previous reports demonstrated that PTEN induced cell cycle arrest by decreasing the 
number of cells in S phase, which is indicative of S-phase entry inhibition (Paramio et al., 
1999). Consistent with this, we saw that BPH-1 cells with PTEN knocked down had an 
increased fraction of cells in the S and G2/M phases of the cell cycle (Figure 4-2, E b and 
c). Cell cycle analysis was also consistent with proliferation where we observed that PTEN 
knock down cells proliferated faster than control cells (Figure 4-2, E a).  
 
Partial loss of PTEN expression drove BPH-1 cells to grow as an invasive tumor To 
determine whether PTEN loss could exert a tumorigenic effect on prostate cells in vivo, 
100k BPH-1
PTENsh 
or control epithelial cells were recombined with 300k rUGM cells and 
grafted under the kidney capsule of SCID mice. The grafts were harvested after 4 weeks. 
The results showed that recombinants contains BPH-1
PTENsh 
cells were significantly larger 
grafts than BPH-1
PSR 
containing recombinants (Figure 4-3, A, P<0.01). These results were 
consistent with our in vitro observations. Grossly, control grafts formed white solid cores. 
Histologically, they exhibited the formation of solid epithelial cords surrounded by a 
muscular stroma, as previously described (Cunha et al., 2002). There were sharp 
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delineations between the grafts and the host kidney with no sign of invasion (Figure 4-3, 
B a and b). In clear contrast, based on gross observation the grafts using PTEN 
knockdown epithelium contained areas where blood vessels were formed and areas 
composed of either cysts or necrotic tissue. The histological appearance of the 
BPH-1
PTENsh
 + rUGM grafts, as assessed by H & E staining and SV-40 T-antigen staining, 
resembled a poorly differentiated carcinoma phenotype (Figure 4-3, B e and f). There was 
heterogeneity in the resultant tumors in that some cases grew as noninvasive proliferative
 
lesions on the surface of the host kidney, some contained individual cells with large 
nuclei and dense cytoplasm scattered with stroma, while others formed invasive
 
lesions 
that engulfed and destroyed kidney tissue (Figure 4-3, B e and f). Irregular areas of 
necrotic tissue also extended throughout the grafts with positive SV-40 T antigen staining 
which confirmed the BPH-1 cell origin of the tumor epithelium (Figure 4-3, B f and inset). 
Invasion and infiltration into the kidney were observed. Previous unpublished data showed 
that LNCaP + rUGM grafts contained much less stroma compared with BPH-1 + rUGM 
grafts, indicating a rapid tumor growth. The same observation was also seen  in 
recombinants of c-myc overexpressing epithelial cells with rUGM (Williams et al., 2005). 
The present chapter also showed that no fibromuscular stroma was observed in the 
invading area. Tumor cells invaded the kidney and engulfed nephrons after 1 month of 
growth. In contrast, control grafts did not invade the kidney and graft epithelium was 
separated from kidney by a stromal layer. Well defined epithelial cell junctions 
demonstrated by E-cadherin staining were noted (Figure 4-3, B c). In the PTEN 
knockdown cells, E-cadherin expression was almost absent, consistent with the malignant 
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phenotype (Figure 4-3, B g). BPH-1
PTENsh
 cells have significantly elevated phosphorylated 
histone H3 (pHisH3) cells throughout the grafts compared with control grafts (Figure 3 B, d 
and h, 0.7/100m2 positive cells in BPH-1PSR grafts, 4.33/100m2 positive cells in 
BPH-1
PTENsh 
grafts, P<0.001). These data show that a moderate suppression (55%) PTEN 
in BPH-1 cells not only significantly increased motility and promoted cell proliferation, 
and invasion in vitro, but also was sufficient to induce malignant transformation and 
invasion in vivo. 
 
Suppression of PTEN in BPH-1 cells caused a loss of stromal differentiation 
Immunohistochemical analysis was used to assess the effect of epithelial cells on adjacent 
stroma. The three markers used, vimentin, smooth muscle -actin, smooth muscle -actin, 
representing respectively, a fibroblastic marker, an early marker of smooth muscle 
differentiation, and a late marker of smooth muscle differentiation. The stromal cells in 
BPH-1
PSR
 + rUGM tissue recombinants had abundant -actin and -actin expression, but 
almost no vimentin expression (Figure 4-3, C a, b and c), which indicated a well 
differentiated stroma surrounding the epithelium. In stromal cells of BPH-1
PTENsh
 + rUGM 
tissue recombinants, there was suppression of -actin expression, moderate -actin 
expression(Figure 4-3C, d) and induction of vimentin expression (Figure 4-3, C f, arrow 
and I), indicating poorly differentiated stroma correlating with a cancer phenotype.  
 
Activation of Akt signaling pathway elicited an atypical hyperplasia phenotype 
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To determine whether constitutive activation of Akt could exert a tumorigenic effect on 
prostate cells in vivo, 100k BPH-1
Akt 
cells (generated as described as previously- ((Ao et 
al., 2006)) or BPH-1 cells were recombined with 300k rUGM and grafted under the 
kidney capsule of SCID mice. The grafts were harvested after 4 weeks. The BPH-1
Akt 
cells formed larger grafts under the induction of rUGM, compared with BPH-1
 
groups 
(data not shown). Histologically, both control grafts and Akt overexpressing grafts had 
sharp delineations from the host kidney with no sign of invasion (Figure 4-4, A a and e). 
However, the BPH-1
Akt
 cells formed small solid cord structures and many cells had 
enlarged and elongated nuclei, which indicated an atypical hyperplasia  phenotype 
(Figure 4-4, A e). Both BPH-1 and BPH-1
Akt
 cells continued to express SV-40 T antigen 
(Figure 4-4, A b and f). Control grafts had well defined cell junctions demonstrated by 
E-cadherin staining (Figure 4-4, A c). E-cadherin expression was almost absent in the 
BPH-1
Akt
 cells consistent with a malignant phenotype (Figure 4-4, A g). BPH-1
Akt 
cells 
have significantly increased number of pHisH3 positive cells throughout the grafts 
compared with control grafts (Figure 4-4, A d and h, 0.3/100m2 positive cells in 
BPH-1grafts, 2.33/100m2 positive cells in BPH-1Akt grafts, P<0.01). These data showed 
activation of Akt in BPH-1 cells could also promote cell proliferation, and induce 
transformation in vivo.  
 
Activation of Akt in BPH-1 cells caused a loss of stromal differentiation 
The stromal cells in BPH-1 + rUGM tissue recombinants had a well differentiated stroma 
with abundant -actin and -actin expression, but very low vimentin expression (Figure 
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4-4, B a, b and c). In stromal cells of BPH-1
Akt
 + rUGM tissue recombinants, there was 
suppression of -actin expression, moderate expression of -actin (Figure 4-4, B d) and 
induction of vimentin expression (Figure 4-4, B f, arrow and I), consistent with a poorly 
differentiated stroma. 
 
The effect of PTEN knock down is consistent by using a new human prostatic 
epithelial cells line 
In order to assess whether the results obtained in BPH-1 cells were consistent we repeated 
the experiments using a new human prostatic epithelial cell line PrE3, which has been 
immortalized by retrovirally introduced SV-40 T antigen by retroviral infection. These 
cells give rise to a normal-appearing glandular structures when recombined with rUGM 
(Figure 4-5, A a) In order to test the consequences of suppression of PTEN in these cells, 
PTEN knocked down and control constructs were retrovirally infected to PrE3 cells. The 
knocked down cells were then grafted under the renal capsule of SCID mice after 
recombined with rUGM. After 5 months of growth under the kidney capsule of SCID 
mice, PrE3
PSR
 + rUGM tissue recombinants formed glandular structures, Ku 70 
immunofluorescence staining and SV-40 T antigen staining (data not shown) were 
positive in the nuclei of the epithelial cells, indicating that the glands were formed from 
the grafted human cells. (Figure 4-5, A b). In contrast,  in + rUGM tissue recombinants 
the epithelial cells formed large solid cords with enlarged nuclei (Figure 4-5, A f). 
Multilayered cells forming nests recapitulated a PIN structure. Since the parental PrE3 
cells formed normal glandular structure, knocking down only one tumor suppressor even 
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in the face of SV-40 may not be enough for these cells to undergo malignant change. 
PrE3
PTENsh
 cells continued to express Ku 70 (Figure 4-5 A, g) and SV-40 T antigen (data 
not shown). Consistent with the consequences of suppression of PTEN in BPH-1 cells, 
recombinants of PrE
PTENsh 
+ rUGM showed expression of vimentin in adjacent stroma 
(Figure 4-5A, j). The stromal cells in PrE3
PSR
 + rUGM and PrE3
PTENsh
 + rUGM grafts 
expressed -actin and actin (Figure 4-5, A c, d, h and i). Epithelial cells in both control 
and knock down recombinants continuously expressed AR (Figure 4-5, B a and e). 
E-cadherin staining was positive at the cell-cell junctions of control recombinants (Figure 
4-5, B b), however, in the PTEN knockdown recombinants, staining was patchy and,
 
in 
many places, undetectable (Figure 4-5, B f). PrE3
PTENsh
 cells proliferated much faster in 
vivo than control PrE3
PSR 
cells, demonstrated by significantly increased pHisH3 positive 
cells (Figure 4-5, A d and h, 0.3/100m2 positive cells in PrE3 grafts, 3/100m2 positive 
cells in PrE3
PTENsh 
grafts, P<0.01). pHisH3 positive cells could only occasionally be found 
in control grafts (Figure 4-5, B c and g). CK 14 expression was absent in PrE
PTENsh
 cells, 
indicating that as PIN lesions progressed, basal cells were lost. In contrast, normal glands 
were CK14 positive in the basal layer (Figure 4-5, B d and h). 
 
Constitutive expression of myrislated Akt in PrE3 cells caused a high-grade 
cribriform PIN phenotype 
In order to confirm the consequences of PTEN suppression in prostate cancer 
progression, we retrovirally overexpressed Akt in PrE3 cells. After 5 months of growth 
under the kidney capsule of SCID mice PrE3
pLNCX-control
 + rUGM tissue recombinants 
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formed benign appearing glandular structures (Figure 4-6, A a), with Ku 70-positive 
nuclei. PrE3
myr-Akt
+ rUGM tissue recombinants fused into large ducts lined with epithelial 
cells with a cribriform high grade PIN-like structure (Figure 4-6, A f). Cells in these 
structures continued to express Ku 70 (Figure 4-6, A g). There were multiple epithelial 
layers in the cords and cells have enlarged nuclei consistent with a PIN phenotype. 
PrE3
myr-Akt 
cells had induced vimentin expression in stroma (Figure 4-6, A g and j). 
-actin and -actin expression did not change much in the rUGM compared with control 
recombinants. Both control and knock down recombinants expressed AR (Figure 4-6, B a 
and e). E-cadherin expression was detected in cell-cell junctions of control recombinants 
(Figure 4-6, B b), however, the PrE3
myr-Akt
 cells had decreased E-cadherin staining 
(Figure 4-6, B f). PrE3
myr-Akt
 cells proliferated significantly faster in vivo than control 
PrE3
pLNCX-control 
cells as demonstrated by increased pHisH3 staining (0.3/100m2 positive 
cells in PrE3
pLNCX-control
  grafts, 1.7/100m2 positive cells in PrE3myr-Akt grafts, P<0.01).  
(Figure 4-6, B c and g). Control glands retained CK14 expression in the basal layer. 
However, lack of CK 14 expression in structures generated by PrE3
myr-Akt
 cells indicated 
that basal cells were lost. (Figure 4-6, B d and h).  
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               non-tumorigenic                   tumorigenic 
 
Figure 4-1. PTEN protein expression in a panel of human prostatic epithelial cells and 
internal mutation or deletion of PTEN in BPH
CAFTD
 cell lines. (A) Western blotting was 
performed to examine PTEN protein expression levels in malignant (BPH-1
CAFTD1
, 
BPH-1
CAFTD2
, DU145, LNCaP and PC3) and non-tumorigenic (PrE1, 957E/hTERT, PrE3 
and BPH-1) prostatic epithelial cell lines. The PrE1, 957/hTERT, PrE3 cells had the 
highest PTEN expression compared with other transformed prostate cell lines. BPH-1 cells 
had a moderate level of PTEN expression. These two bands might correspond to two 
isoforms of the PTEN protein 
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Figure 4-1 (B) Two obvious insertions (9 bp and 15 bp) and one deletion (28 bp), all 
highlighted, were found in BPH
CAFTD1
 cells in the 5’UTR region of the mRNA.  
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Figure 4-2. In vitro assays for BPH-1
PSR
 and BPH-1
PTENsh
 cells. (A) In order to examine 
the role of PTEN in prostate cancer progression, PSR (control - BPH-1
PSR
) and PTEN 
knock down (BPH-1
PTENsh
) BPH-1 cell lines were generated by stable retroviral infection. 
PTEN downregulation in BPH-1
PTENsh
 was confirmed by western blotting and band 
intensity quantitated. There was 55% PTEN protein downregulation and 2.2 fold pAKT 
upregulation in BPH-1
PTENsh
 cells. 
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Figure 4-2 (B). Wound healing assay. BPH-1
PTENsh
 closed wounds in the confluent 
monolayer significantly faster than BPH-1
PSR
 cells. Images (left) and quantitation (right) 
shown. Student’s t-test, P<0.001. 
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Figure 4-2 (C). Transwell migration study. BPH-1
PTENsh
 migrated through the uncoated 
Boyden chamber significantly faster than BPH-1
PSR
 Representative phase-contrast optical 
photomicrographs after overnight culture shown (a, left) and quantitated (a, right). 
Student’s t-test, P<0.01. (D) Invasion assay. BPH-1PTENsh cells had increased invasive 
ability in a Matrigel coated Boyden chamber invasion assay compared to 
BPH-1
PSRRepresentative phase-contrast optical photomicrographs after overnight culture 
shown (left) and quantitated (right). Student’s t-test, P=0.01. 
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Figure 4-2 (E). Cell cycle analysis and proliferation assay. BPH-1 cells with PTEN 
knockdown had an increased fraction of cells in the S and G2/M phases of the cell cycle (a 
and b). PTEN knockdown promoted BPH-1 cell proliferation significantly over control 
growth rate. (Student’s t-test, P<0.001) (c).  
 134 
 
 
 
Figure 4-3. In vivo comparisons of BPH-1
PSR
 and BPH-1
PTENsh
 cells. (A). BPH-1 
PTENsh 
cells (right) formed significantly larger grafts than control (left) after 3 months of growth 
under the kidney capsule of SCID mice (P<0.01).   
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Figure 4-3 (B) (a). H & E staining and SV-40 T-antigen staining demonstrated that 
BPH-1
PTENsh
 cells invaded to kidney (e, f and inset). E-cadherin was clear in cell-cell 
junctions of control grafts (c), however, E-cadherin expression was low in the PTEN knock 
down cells (g). BPH-1
PTENsh
 cells had increased pHisH3 positive cells (h) indicating 
increased proliferation compared with control.  
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Figure 4-3 (C). Suppression of PTEN in BPH-1 cells caused a loss of stromal 
differentiation. BPH-1
PSR
 + rUGM tissue recombinants had abundant -actin and -actin 
expression, but almost no vimentin expression (a, b and c) In BPH-1
PTENsh
 + rUGM tissue 
recombinants, there was suppression of -actin expression (d and g), no significant change 
of - actin expression (e and h) and induction of vimentin expression (f and i) 
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Figure 4-4. Activation of Akt signaling pathway elicited a atypical hyperplasia 
phenotype. (A) Both control grafts and Akt overexpressing grafts had no sign of invasion 
(a and e). BPH-1
Akt
 cells formed smaller solid cord structures and many cells had 
enlarged and elongated nuclei within the cords which indicated a atypical hyperplasia 
phenotype (e). Both BPH-1 and BPH-1
Akt
 cells continued to express SV-40 T antigen (b 
and f). Control grafts had clear cell junctions demonstrated by E-cadherin staining (c). 
E-cadherin expression was almost absent in the BPH-1
Akt
 cells (g). BPH-1
Akt 
cells have 
significantly increased number of pHisH3 positive cells throughout the grafts. 
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Figure 4-4 (B). Activation of Akt in BPH-1 cells caused a loss of stromal differentiation. 
The stromal cells in BPH-1 + rUGM tissue recombinants had abundant -actin and -actin 
expression, but almost no vimentin expression (a, b and c). In stromal cells of BPH-1
Akt
 + 
rUGM tissue recombinants, there was suppression of -actin expression (d) and induction 
of vimentin expression (f, arrow and I).  
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Figure 4-5. The effect of PTEN knock down is consistent by using a new human prostatic 
epithelial cells line. (A) PrE3
PSR
 + rUGM tissue recombinants formed glandular structures 
after 5 months post grafting (a) with positive Ku 70 staining (b). PrE3
PTENsh 
+ rUGM 
tissue recombinants formed a PIN lesion (f). Cells continuously expressed Ku 70 (g) with 
induced vimentin expression (j). No obviousactin and -actin change was found in the 
PIN lesion (h and I) compared with control (c and d).  
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Figure 4-5 (B) Epithelial cells in both control and knock down recombinants continued to 
express AR (a and e). E-cadherin was positive in cell-cell junction of control 
recombinants (b), but E-cadherin expression was patchy in the PIN lesion (f). Increased 
pHisH3 positive cells in PrE3
PTENsh
 cells ((g and inset (higher magnification)) than 
control PrE3
PSR 
cells (c). CK 14 expression was negative in PrE3
PTENsh
 cells (h), but the 
normal glands were CK14 expression in the basal layer (d).  
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Figure 4-6. Constitutive expression of myrislated Akt in PrE3 cells caused a high grade 
cribriform PIN phenotype. (A) PrE3
pLNCX-control
 + rUGM tissue recombinants formed 
glandular structures 5 months post grafting (a) with positive Ku 70 immunofluorescence 
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staining (b). In clear contrast, cells in PrE3
pLNCX-myr-Akt 
+ rUGM tissue recombinants 
formed a high grade PIN lesion in which cells fused into a big nest with enlarged nuclei 
(f). Cells continuously expressed Ku 70 (g) with induced vimentin expression (j). No 
obvious–-actin and -actin change was found in the PIN lesion (h and i) compared with 
control (c and d). 
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Figure 4-6 (B). Suppression of PTEN in less initiated prostate epithelial cells caused a 
hyperplasia phenotype. (B) Epithelial cells in both control and knock down recombinants 
continued to express AR (a and e). E-cadherin was positive at cell-cell junctions of 
control recombinants (b), but E-cadherin expression was lost in the PIN lesion (f). 
Increased pHisH3 positive cells in PrE3
PTENsh
 cells ((g and inset (higher magnification)) 
than control PrE3
PSR 
cells (c). CK 14 expression was negative in PrE3
PTENsh
 cells (h), but 
the normal glands retained CK14 expression in the basal layer (d). 
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Discussion 
Loss of PTEN expression has been detected in many cancers including prostate (Di 
Cristofano et al., 2001; Di Cristofano et al., 1998). Elevation of Akt is a common 
response to the loss of the PTEN tumor suppressor gene (Cantley and Neel, 1999) and 
occurs frequently in human prostate cancer (Davies et al., 1999; Li et al., 1997). When 
PTEN activity was restored in PTEN null cells, Akt expression was suppressed, which 
directly links PTEN to Akt activity (Davies et al., 1999; Myers et al., 1998; Stambolic et 
al., 1998).  
 
We determined that BPH-1 derived tumorigenic cell lines and a subset of prostate cancer 
cell lines had lower PTEN expression compared with parental BPH-1 and other 
non-malignant human prostatic epithelial cell lines. These molecular characteristics are 
consistent with differences between normal and malignant cells in primary prostate cancer, 
in which PTEN expression was downregulated in tumorigenic cells. Mutations, additions 
and deletions of PTEN genomic DNA were found in the noncoding 5’UTR of the PTEN 
gene in tumorigenic cells, but not in the benign parental BPH-1 cells. It has recently been 
reported that the long 5’UTR sequences of PTEN contains a promoter that is responsible 
for constitutive PTEN expression(Han et al., 2003). This promoter was mapped to the 
region between –551 and –220 bases upstream of the translation start site. The region 
where we found deletions contains multiple binding sites for transcription factors such as 
Sp1.Down-regulation of PTEN expression could be due to loss of this promoter activity 
(Ma et al., 2005a). Thus we speculate that PTEN downregulation in BPH-1
CAFTD
 cells may 
also due to loss of this second promoter activity. Deletions in this region my possibly affect 
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PTEN promoter activity in the 5’UTR. However, at this point it is not clear whether or not 
this area of the human 5’UTR contains the  promoter and important transcription factor 
binding sites. In the future, a luciferase reporter assay should be performed to explore this 
hypothesis and to find candidate transcription factors which can constitutively activate the 
promoter in 5’UTR. 
 
In this chapter, we made a PTEN knock down BPH-1 cell line to examine the consequences 
of loss of PTEN in benign prostate cells both in vitro and in vivo. BPH-1
PTENsh 
cells had 
enhanced proliferation, mobility, and invasion as compared with control cells. We were 
able to show that partial suppression of PTEN expression in the presence of SV40 was 
sufficient to drive human prostatic epithelium to form invasive tumors within the in vivo 
tissue recombination model. The BPH-1
PTENsh
 cells retained expression of  SV-40 T 
antigen and proliferated faster than control cells in vivo. Retroviral infection of BPH-1 cells 
with the control plasmid resulted in a benign solid cord structure. Suppression of PTEN 
produces a cancer phenotype within our xenograft model that is progressive and invasive. 
The resulting tumors resemble a poorly differentiated invasive advanced carcinoma. A 
single addition of a dominant
 
acting oncogene may be sufficient to convert a 
non-tumorigenetic
 
cell to a fully tumorigenetic cell. Such as overexpression of c-MYC in 
benign prostate epithelium caused a cancer phenotype (Williams et al., 2005). This 
observation emphasized the importance of genetic changes as key determinants of 
malignancy. The BPH-1 cells were SV-40 T-antigen initiated, but this is insufficient per se 
to produce a tumor. The levels of PTEN suppression by a retroviral delivery system would 
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certainly constitute an additional molecular hit. The in vitro and in vivo data indicated the 
important role of PTEN in transformation of cells at early stages of tumor progression.  
 
We went on to suppress PTEN in another initiated prostatic epithelial cell line (PrE3) and 
saw similar in vivo consequences to those seen in BPH-1 cells . However, PrE3 cells 
formed well differentiated glandular structures in the tissue recombination model. 
Knocking down PTEN in the PrE3 cells caused a PIN phenotype instead of an invasive 
tumor. To our knowledge, no data have been reported concerning the role of PTEN in 
initiating prostate cancer progression in vivo because of the lack of normal human prostatic 
cell lines. Our data provide new insights into the role of this lesion in prostate cancer 
progression. 
 
Loss of PTEN expression can be a pivotal point in the cellular decision-making process that 
determines if a cell will undergo proliferation. PTEN suppression within the BPH-1 cells 
and PrE3 cells appeared to exhibit a proliferative effect which was demonstrated by 
elevation of pHisH3 positive cells. The lack of expression of the basal cell marker CK14 
indicated that the PTEN knock down tumor, like human prostate adenocarcinoma, loses 
basal cells during tumor formation. The same phenomenon was also seen in PrE3
PTENsh
 PIN 
lesions. In the glands formed by PrE3 control cells, CK14 expressing cells clearly 
surrounded luminal cells, which confirmed the benign nature of these cells. 
 
The hallmark of malignancy is the acquisition of an invasive phenotype. This process may 
 147 
involve breakdown of cell-cell junctions, increased motility, and increased proliferation of 
the tumor cells. One of the cell-cell junction molecules, E-cadherin, exerts a critical role in 
the control of tumorigenicity. It is subjected to inactivation by multiple mechanisms 
including genetic and epigenetic events (Kotelevets et al., 2001). It was suggested that 
PTEN might participate in tumor cell invasion through stabilizing cell-cell junctions in 
kidney tumorigenic cell lines in vitro (Kotelevets et al., 2001). Transient reduction of 
PTEN expression by RNAi induces loss of cell adhesion (Mise-Omata et al., 2005). Our 
data suggested that when PTEN expression is partially lost in BPH-1 cells, they gained 
invasive ability and lost E-cadherin expression in vivo. The same phenomenon was seen in 
the PIN lesions formed by PrE3
PTENsh
 cells. Decreased or absent E-cadherin expression is a 
common occurrence in human prostate cancer (Rokhlin and Cohen, 1995; Umbas et al., 
1992). Failure to detect E-cadherin expression may suggest cancer development in partial 
loss of PTEN model, which clearly correlates with the difference between normal and 
tumor cells in cancer patients.  
 
Normal prostatic stroma predominantly expresses -actin and actin, but not vimentin, 
while tumor stroma expresses predominantly vimentin with some actin (Hayward et al., 
1996). Our unpublished data demonstrated that LNCaP + rUGM tissue recombinants little 
-actin expression and that most stromal cells had strong vimentin expression. This result 
correlated with the differences that we and others have seen in clinical samples. Our data 
suggested that partial loss of PTEN in epithelium resulted in a more 
fibroblastic/myofibroblastic stroma with a downregulation of actin and upregulation of 
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vimentin, consistent with a reactive stroma. These observations reflected the importance 
of PTEN in regulating stromal differentiation and thus stromal-epithelial interactions and 
in human prostate cancer progression. Homozygous deletion of PTEN is lethal, while 
heterozygote PTEN mice develop mPIN but only progress to an invasive phenotype after 
another genetic hit (Abate-Shen et al., 2003; Di Cristofano et al., 2001; Kim et al., 2002). In 
this human model we showed an accelerated progression after partial loss of PTEN in 
BPH-1 cells because the epithelium is already SV40 immortalized.  
 
Akt is downstream PTEN signaling pathway and is constitutively activated in many 
cancers including prostate cancer (Nicholson and Anderson, 2002). We showed that the 
PTEN/Akt axis is important in human prostate cancer progression. Constitutive 
overexpression of Akt in both BPH-1 and PrE3 cells accelerated cell growth in vivo, 
demonstrated by increased numbers of pHisH3 positive cells. Out studies showed that loss 
of PTEN and constitutively activation of Akt protein can have dramatically different effects 
on tumor physiology. The recombinant of BPH-1
Akt
 + rUGM formed an atypical 
hyperplasia structure instead of an invasive tumor. A critical downstream effector of Akt, 
which contributes to tumorigenesis, is mTOR (Hay and Sonenberg, 2004). Constitutively 
Akt activation activates mTOR and at the same time mTOR activation inhibits Akt via an 
inhibitory feedback mechanism to controls cell proliferation and tumor progression. 
However, the loss of even one copy of PTEN may be sufficient to overcome this feedback 
mechanism, reactivate Akt, and dramatically enhance tumor severity and produce a 
different phenotype (Manning et al., 2005). 
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Since PrE3 cells formed benign glandular structures, which indicated a less initiated 
phenotype compared with BPH-1 cells, which loss the ability to form glandular structure. 
The more aggressive PIN structures in PrE3
myr-Akt
 grafts suggested that Akt activation is a 
further downstream effect of PTEN loss in human prostate cancer. The phenotype of the 
tissue recombinants was similar to what was seen in PTEN knock down recombinants. The 
present study demonstrated the contribution of an individual gene to carcinogenesis. This is 
an approach which we have successfully applied to the overexpression of the c-myc 
proto-oncogene in human prostatic epithelial cells resulted in a new in vivo model in 
which benign human prostatic epithelial cells undergo malignant transformation to form 
metastatic tumors with continued expression of key markers such as PSA and AR.  
 
In summary, our current work developed less aggressive models representing distinct 
grades of disease, with defined stage progression. Such models can be a target of 
molecular interrogation to determine how common genetic alterations affect prostate 
cancer phenotypes and lead to further genetic changes in response  to common 
therapeutic strategies such as androgen ablation. 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
The stromal microenvironment can either positively or negatively regulate tumor 
progression, however it is still unclear why the environment plays a dual role. The 
mechanistic basis for stromal programming is not completely understood. Many 
molecules and pathways play important roles in controlling proliferation, differentiation, 
and function of both epithelial and stromal cells. In adulthood, normal prostatic epithelial 
growth is regulated by reciprocal interactions between smooth muscle  and epithelial 
cells.  These interactions are mediated by the local synthesis and action of paracrine 
signaling molecules (Hayward et al., 1997). Signaling abnormalities between smooth 
muscle and epithelial cells may either actively promote carcinogenesis or permit the 
progression to anaplasia via loss of normal homeostatic controls (Hayward et al., 1998). 
Leland Chung’s group reported that co-inoculation of tumorigenic Nbf-1 fibroblasts (an 
androgen-sensitive rat prostate fibroblast cell line) with human PC-3 cells accelerated 
tumor growth (Chung, 1995; Chung et al., 1981; Chung et al., 1991). The Cunha 
laboratory has indicated, using an in vivo model, that CAFs were capable of stimulating 
carcinogenesis and inducing the malignant progression of an initiated epithelium (BPH-1 
cell line), while normal prostatic fibroblasts were incapable of stimulating such 
progression (Hayward et al., 2001; Olumi et al., 1999; Orimo et al., 2005)Other 
laboratories have made observations consistent with this result (Barclay et al., 2005; 
Hayward et al., 2001; Olumi et al., 1999; Orimo et al., 2005). Thus, the process of 
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prostatic carcinogenesis may include aberrations in the interactions of the prostatic 
epithelium, with its smooth muscle microenvironment resulting in reciprocal 
de-differentiation of both the emerging carcinoma cells and the prostatic smooth muscle. 
It is also possible that the stromal changes observed occur through the recruitment of 
other cell types such as macrophages or other bone marrow-derived cells. A detailed 
understanding of the signaling mechanisms between stroma and epithelium will allow 
design of therapies aimed at inhibiting prostate tumor growth. We have found that TGF- 
expression is elevated in CAFs versus normal prostatic fibroblasts, which promotes 
invasion of tumorigenic but not non-tumorigenic cell lines (Ao et al., 2006). Crosstalk 
between a paracrine-acting cytokine (TGF- and chemokine pathways (SDF-1/CXCR4) 
promotes malignant progression of BPH-1 cells (Ao et al., 2007). Recently, it was shown 
that TGF- is one of the fibroblast-supplied factors involved in suppression of epithelial 
transformation (Bhowmick et al., 2004a; Bhowmick et al., 2004b). Loss of TGF- 
responsiveness in fibroblasts resulted in PIN through the activation of the paracrine 
hepatocyte growth factor (HGF) pathway (Bhowmick et al., 2004a; Bhowmick et al., 
2004b). These data indicate that TGF-inhibits cell growth in non-transformed prostatic 
cells, but functions in a pro-oncogenic manner in transformed prostatic cells. TGF-is 
one important paracrine mediator of stromal-epithelial interactions, and is essential for 
stromal programming to promote adjacent epithelial tumor progression. However, the 
paracrine environment is complex and other important mediators of paracrine signaling 
and tumor progression that are waiting to be investigated. Changes in the epithelial and 
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stromal cells which modulate this signaling environments are not well understood and are 
a focus of this work.  
 
In chapter II, I examined the consequences of manipulating cell proliferation in both 
epithelial and stromal cells by overexpressing cyclin D1. I observed that cyclin D1 
overexpressing BPH-1 cells did not become tumorigenic under the influence of inductive 
rUGM in the tissue recombination model. However, the cyclin D1 overexpressing cells 
did have a higher proliferation rate in vitro and in vivo. These data underline the 
important point that increased proliferation per se is insufficient for malignant 
transformation of epithelial cells even in the face of SV-40 T-antigen expression. 
However, overexpression of cyclin D1 in NPF cells is sufficient to drive adjacent BPH-1 
cells to become tumorigenic, an observation confirmed by the transformation of 
BPH-1
NPF-cyclin D1
 cells. These observations indicate that upregulation of proliferation as 
well as changes in stromal gene expression can change the environment to promote 
carcinogenesis in less damaged epithelium. This underlines the idea that carcinoma is not 
solely a disease of epithelial cells but is a product of both the damaged epithelium and an 
altered microenvironment.  
 
In chapter III, I proposed a possible mechanism for prostate cancer progression which 
involved stromal-epithelial interactions. Our data indicated that cathepsin D is a crucial 
mediator between BPH-1 and either NPF
cyclin D1 
or CAFs in vitro and in vivo. Cathepsin D is 
upregulated in both NPF
cyclin D1 
cells and CAFs as determined by microarray and western 
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blot analysis. My study demonstrated that cathepsin D plays a crucial role in prostatic 
fibroblast outgrowth and may favor prostate tumor progression acting via a paracrine 
loop. Cathepsin D is overexpressed and secreted by fibroblasts, and is captured in vivo by 
epithelial cells. The resultant cathepsin D overexpression in tumor epithelium promotes 
proliferation, motility, and invasion of epithelium and consequently enhances tumor-host 
homeostasis. The identification of factors such as cathepsin D that participate in the 
tumor-stroma communication might be crucial for the development of stromally-targeted 
therapy of prostate cancer. 
 
In chapter IV, I defined the role of clinically observed genetic lesions in deregulating 
stromal differentiation. The ability of epithelial cells with defined alterations to establish 
and maintain smooth muscle differentiation in adjacent stromal cells was examined. 
Partial suppression of PTEN in the presence of SV40T expression is sufficient to initiate 
malignant transformation of human prostatic epithelium and caused high-grade PIN in 
benign PrEs. The ability of human prostatic epithelial cells to induce and maintain smooth 
muscle differentiation in adjacent stroma was shown to be negatively correlated to the 
level of genetic damage sustained by those epithelial cells. 
 
The aim of this project was to examine how an oncogene (cyclin D1) and a tumor 
suppressor (PTEN) might affect stromal-epithelial interactions with the goal of building 
new models of human prostate cancer in vivo. A summary of this project is shown in 
Figure 5-1. Specifically, expression of cyclin D1 or PTEN are either positively or 
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negatively regulated in human prostatic epithelial or stromal cells. The effects of these 
changes are then assessed in tissue recombination models. This approach has been 
successfully applied to the overexpression of the c-myc proto-oncogene in human 
prostatic epithelial cells resulting in malignant transformation to form metastatic tumors 
with continued expression of key molecules such as PSA and the androgen receptor 
(Williams et al., 2005). In this project, we aimed to develop less aggressive models that 
represent distinct grades of disease. Such models can be a target of molecular 
interrogation to determine how these common genetic alterations affect prostate cancer 
phenotypes and lead to further genetic changes in response to common therapeutic 
strategies such as androgen ablation. 
In summary, I found that by manipulating the proliferation of stromal fibroblasts by 
overexpressing cyclin D1 could alter the microenvironment  resulting in the 
transformation of initiated BPH-1 cells through paracrine signaling. Cathepsin D was 
proposed to be an important mediator in these stromal-epithelial interactions. I also found 
that genetically modified epithelium (loss of PTEN) had reduced ability to induce and/or 
maintain smooth muscle differentiation in adjacent stromal cells, consistent with changes 
seen in the stromal cells adjacent to tumors in clinical samples. 
 
Cyclin D1 degradation is mediated by phosphorylation and ubiquitin-dependent 
proteolysis (Diehl et al., 1997). Glycogen synthase kinase-3ß (GSK-3) phosphorylates 
cyclin D1 leading to cyclin D1 ubiquitination and proteasomal degradation (Diehl et al., 
1998). GSK-3 is phosphorylated and deactivated by Akt and GSK-3activity is elevated 
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by overexpression of PTEN (Ohigashi et al., 2005). When PTEN expression is knocked 
down, GSK-3activity is reduced and less cyclin D1 is degraded by phosphorylation. 
However, the accumulation of cyclin D1 in epithelial cells are not enough to drive cells to 
undergo malignant transformation. In addition to its role in regulating the AKT cell 
survival pathway, PTEN also suppresses the mitogen-activated protein (MAP) kinase 
signaling pathway and interact with integrin signaling pathways. Therefore, the phenotypes 
in PTEN knocked down cell in epithelial cells may be caused by cyclin D1-independent 
pathways. In the future, MAP kinase and integrin pathways will be examined if they are 
involved in the invasive phenotype in BPH-1
PTENsh
 cells. I examined the function of PTEN 
in epithelial cells in this project. However, the function of PTEN in stromal environment is 
waiting to be dissected and the link between PTEN and cyclin D1 in stroma can be studies 
in the future. 
 
Prostate cancer research has been hindered by lack of well established, characterized, 
immortalized benign prostatic epithelial cells lines that express markers of normal 
prostatic epithelial cells. Such cells can be used to study multi-step carcinogenesis, cancer 
progression, and potential therapeutic agents to inhibit prostate cancer growth. The 
BPH-1 cell line is one such cell line that has been widely used in prostate cancer research. 
It is by far the only line which starts off benign an can be pushed to a malignant 
phenotype by either genetic modification or hormone treatment. The cells do not form 
tumors in SCID mice until 1 year post-grafting, which makes them an appropriate model 
to study tumor progression and stromal-epithelial interactions. However, BPH-1 cells are 
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SV-40 immortalized, and they do not form glandular structures in vivo. Dr. Ming Jiang in 
our laboratory developed a spontaneously immortalized prostate epithelial cell line, which 
is designated as PrE1. These cells give rise to normal glandular structure when 
recombined with rUGM. In the future, more genes and pathways which might be 
involved in stromal-epithelial interactions can be fully investigated using this new 
prostatic epithelial cell line.  
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Figure 5-1. Working model of this project. Cyclin D1 overexpressing BPH-1 cells did not 
become tumorigenic under the influence of inductive rUGM in the tissue recombination 
model. However, overexpression of cyclin D1 in NPF cells is sufficient to drive adjacent 
BPH-1 cells to become tumorigenic possibly through upregulation of cathepsin D. Partial 
suppression of PTEN in the presence of SV40-T antigen expression is sufficient to initiate 
malignant transformation of human prostatic epithelium and caused high-grade PIN in 
benign PrE. The ability of human prostatic epithelial cells to induce and maintain smooth 
muscle differentiation in adjacent stroma was shown to be  negatively correlated to the 
level of genetic damage sustained by those epithelial cells. 
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